Date updated: 6/09
Name:
Steven J. Burakoff, M.D.
Address:
Mount Sinai School of Medicine
The Tisch Cancer Institute
One Gustave L. Levy Place – Box 1079
C/o Hematology/Oncology Department
New York, NY 10029
Birth Place:
New York, New York
Education:
1964
1965
1970
1984
B.A.
M.A.
M.D.
M.A.
with Honors, Lehigh University, Bethlehem, Pennsylvania
Queens College, Flushing, New York (Psychology)
Albany Medical College, Albany, New York
(hon.) Harvard University, Cambridge Massachusetts
Postdoctoral Training:
Internships and Residencies:
1970-71
Medical Intern, New York Hospital-Cornell Medical Center, New York,
New York
1971-73
Medical Resident, New York Hospital-Cornell Medical Center
Clinical and Research Fellowships:
1973
Fellow in Immunology, Rockefeller University, New York, New York
(Advisor: Dr. Henry Kunkel)
1973-76
Research Fellow in Immunology, Harvard Medical School, Boston
(Advisor: Dr. Baruj Benacerraf)
Licensure and Certification:
1973
Massachusetts
1973
Diplomate, American Board of Internal Medicine
2001
New York State License 110740-1
Academic Appointments:
1976-77
Instructor of Pathology, Harvard Medical School
1977-80
Assistant Professor of Pathology, Harvard Medical School
1980-83
Associate Professor of Pediatrics, Harvard Medical School
1983-00
Professor of Pediatrics, Harvard Medical School
1995-00
Ted Williams Senior Investigator, Dana-Farber Cancer Institute
1998-00
Margaret M. Dyson Professor of Pediatrics, Harvard Medical School
2000-06
Director, Skirball Institute of Biomolecular Medicine, New York
University School of Medicine
2000-07
Laura and Isaac Perlmutter Professor, New York University School of
Medicine
1
2000-07
2007200720092009-
Director, NYU Cancer Institute, New York University School of
Medicine
Director, The Tisch Cancer Institute, Mount Sinai School of Medicine
(formerly the Mount Sinai Cancer Institute)
Professor of Medicine, Hematology and Medical Oncology
Mount Sinai School of Medicine
Acting Chief, Division of Hematology and Medical Oncology,
Department of Medicine, Mount Sinai School of Medicine
Lillian and Henry M. Stratton Professor of Cancer Medicine,
Mount Sinai School of Medicine
Hospital Appointments:
1978-79
Junior Associate in Medicine, Peter Bent Brigham Hospital, Boston,
Massachusetts
1980-00
Associate in Medicine (Hematology-Oncology), Children's Hospital
Medical Center, Boston, Massachusetts
1980-84
Associate Physician, Dana-Farber Cancer Institute
1984-00
Physician, Dana-Farber Cancer Institute
1985-00
Chair, Department of Pediatric Oncology, Dana-Farber Cancer Institute
2000-06
Director, Skirball Institute of Biomolecular Medicine New York University
School of Medicine
2002-07Director, New York University Cancer Institute and Kaplan Comprehensive
Cancer Center
2007Director, The Tisch Cancer Institute
2007Professor of Medicine, Hematology and Medical Oncology
Mount Sinai School of Medicine
2009Acting Chief, Division of Hematology and Medical Oncology,
Department of Medicine, Mount Sinai School of Medicine
Other Professional Positions and Major Visiting Appointments:
1979
Visiting Professor, Centro de Investigacion y de Estudios Avanzados del
Institute Politecnico Nacional, Mexico City, Mexico
1981-82
Visiting Scientist, Weizmann Institute, Rehovot, Israel
1982-85
U.S.- Japan National Cancer Institute Tumor Immunology Exchange Program
1988
U.S. - Japan National Cancer Institute Tumor Immunology Exchange Program
Awards and Honors:
1980-85
American Cancer Society Faculty Research Award
1982
American Society of Clinical Investigation
1988
Honored Speaker, Tohoku Medical Society, Japan
1992
Alpha Omega Alpha
1992
Alpha Omega Alpha Lecturer, Albany Medical College
1992
David A. Talmadge Lecture, Colorado Allergy Society
1994
Horizons in Biomedical Research Lecture, Cleveland Clinic Foundation
1995
Association of American Physicians
1995
Harvard Medical School Excellence in Mentoring Award
1995
Ted Williams Senior Investigator, Dana-Farber Cancer Institute
2
1998
2000
2001
2002
2003
2006
2009
Margaret M. Dyson Professor of Pediatrics, Harvard Medical School
Laura and Isaac Perlmutter Professor, New York University, School of
Medicine
ISI Highly Cited Researcher (1980-2000)
Theobald Smith Alumni Lecture, Albany Medical College
Distinguished Alumnus 2003, Albany Medical College Alumni
Lynne Cohen Foundation Awardee
American Association of Immunologists Lifetime Achievement Award
Major Committee Assignments:
National and Regional
1979-83
Member, Clinical Sciences Study Section, National Institutes of Health
1983-87
Advisory Committee on Immunology and Immunotherapy American Cancer
Society. Vice Chairman for 1986, Chairman for 1987.
1983-86
Member, Program Committee, American Association of
Immunologists, Cochairman for 1984 FASEB meeting, Chairman for l985
and 1986 FASEB meetings.
1988-92
Member, Program Committee, American Association of Immunologists,
liaison to Clinical Immunology Society
1989
Cochairman, FASEB Conference: Cellular and molecular studies of bone
marrow transplantation
1989-90
NIAID Task Force on Immunology and Allergy
1992-95
Member, Executive Committee, 1995 International Congress of
Immunology; Chairman, Finance Committee
1993-98
Member, Scientific Affairs Subcommittee on Transplantation Biology,
American Society of Hematology
1993Member, External Advisory Committee, Division of Clinical Sciences,
Fred Hutchinson Cancer Institute
1994-95
Member, World AIDS Foundation
1994
Member, Ad hoc Advisory Committee, Office of AIDS Research
1994-00
Chairman, Biomedical Research Committee, The Medical Foundation
1994-00
Member, Board of Directors, The Medical Foundation
1995-98
Member, Finance Committee, American Association of Immunologists
1998-01
Member, Finance Committee, Federation of Associations for Experimental
Biology
1999-03Member, Publications Committee, American Assn. of Immunologists
2001Member, Scientific Advisory Board, Cold Spring Harbor Laboratory Cancer
Center
2002Member, External Advisory Board, Baylor College of Medicine Cancer
Center
2002Member, External Advisory Board, University of Massachusetts Medical School
Cancer Center
2003Secretary-Treasurer, American Association of Immunologists
2003Member, External Advisory Board, Albert Einstein College of Medicine
Cancer Center
2005Member, External Advisory Board, St. Jude Research Hospital Cancer Center.
3
20062006200720072007-
External Advisory Board, Boston University School of Medicine Cancer Center
Member, Nominating Committee, Association of American Cancer Institutes
Member, Scientific Review Board, Starr Foundation Consortium.
Member, American Cancer Society Council for Extramural Grants
Damon Runyon Cancer Research Foundation, Board Member
Harvard Medical School
1984-86
Co-director, Hybridomas in Biotechnology and Medicine. Postgraduate
course, Harvard Medical School
1988-91
Member, Faculty Fellowships Committee, Harvard Medical School
1988-00
Member, Committee on Immunology, Harvard Medical School
1989-92
Member, Subcommittee of Professors, Harvard Medical School
1992-93
Member, Ad hoc Committee on Relations with Industry, Harvard Medical
School
1995-00
Member, Promotions and Appointment Committee, Harvard Medical School
1998-99
Member, M.D./Ph.D. Program Review Committee, Harvard Medical School
1998-00
Member, M.D./Ph.D. Committee, Harvard Medical School
Dana-Farber Cancer Institute
1980-81
Member, Animal Care Committee, Dana-Farber Cancer Institute
1981-85
Member, Biomedical Research Support Grant Committee, Dana-Farber Cancer
Institute
1981-87
Chairman, Animal Care Committee, Dana-Farber Cancer Institute
1994-00
Faculty Council, Dana-Farber Cancer Institute
1995-99
Promotion and Appointments Committee, Dana-Farber Cancer Institute
1995-00
Executive Management Group, Dana-Farber Cancer Institute
1995-00
Executive Committee for Research, Dana-Farber Cancer Institute
1996-00
Board of Trustees, Dana-Farber Cancer Institute
1996-00
Elected Member, Executive Committee, Board of Trustees, Dana-Farber
Cancer Institute
1999-00
Executive Committee, Dana-Farber/Harvard Cancer Center
New York University School of Medicine
2000-07
Joint Planning Committee, NYU Cancer Institute
2000-07
Dean’s Research Advisory Committee
2000-07
Chair, Executive Management Committee, NYU Cancer Institute
2003-04
Chair, Search Committee, Chair of Department of Pathology
2003-04
Internal Advisory Committee, National Institute of Environmental Health
Science Center
2004-07
Internal Advisory Committee, Center for AIDS Research
2004-05Member, Dermatology Chair Search Committee
2004-05
Dean’s Steering Committee on Budget
2005-07
Member, Steering Committee, Liaison Committee on Medical Education
(LCME)
2005-07
Internal Advisory Committee, Clinical Research Training Program in
4
Translational Medicine
2006-07
Member, Clinical Translational Science Award External Advisory
Committee.
2006-07Dean's Committee on Institutional Resources (DCIR), Research &
Education Subcommittee
2007Adjunct Professor, Department of Pathology
Mount Sinai School of Medicine:
2007Director of The Tisch Cancer Institute (formerly the Mount Sinai Cancer
Institute)
2007Professor of Medicine, Mount Sinai School of Medicine
2007Professor of Oncological Sciences, Mount Sinai School of Medicine
2008Advisory Board, Institute for Rationalized Medicine
2009:
Search Committee, Chief of Pediatrics
2009:
Search Committee, Chief of Hematology/Oncology
2009:
Search Committee Director of the Genome-Based Research Center
Editorial Boards:
1979-81
1981-85
19811983-96
1985-87
1992-94
1993-96
1995-01
Associate Editor, Journal of Immunology
Section Editor for Tumor Immunology, Journal of Immunology
Editor for Tumor Immunology, Immunologic Research
Editorial Board, Cellular Immunology
Editorial Board, Transplantation
Deputy Editor, Journal of Immunology
Editorial Board, Journal of Clinical Immunology
Editorial Board, Biology of Blood and Marrow Transplantation
Invited Speaker at Professional Meetings:
2006
Second Joint American-Israeli Conference on Cancer, Jerusalem, Israel
June 28-30, 2006
Memberships, Offices and Committee Assignments in Professional Societies:
American Association of Immunologists
Transplantation Society
Clinical Immunology Society
American Society of Hematology
American Society of Clinical Investigation
Association of American Physicians
Molecular Medicine Society
American Society of Clinical Oncology
American Association for Cancer Research
Major Research Interests:
1.
Cellular and molecular immunology
2.
T cell activation and signal transduction
3.
Transplantation immunology
5
Teaching Experience:
Harvard Medical School
1978-80
Lecturer in Immunology and Immunopathology 700
1980
Tutorial in Cellular Immunology
1985-00
Immunology 321, Studies of T cell Activation.
1988
Lecturer in Identity, Microbes and Defense.
1988
Lecturer in Immunology 200, Basic Immunobiology.
1998-01
Codirector in Immunology 212, Lymphocyte Signal Transduction.
1999-00
Lecturer in Immunology 300, Signal Transduction in Immune Cells.
Advising Responsibilities:
Graduate Student Sponsor
Past: Harvard Medical School
1977-80
Paul Billings, M.D., Ph.D.
1978-81
Ofra Weinberger, Ph.D.
1982-89
Michael Petrarca, Ph.D
1985-88
Sheldon Ratnofsky, Ph.D
1985-88
Barry Sleckman, M.D., Ph.D.
1987-90
John Park, M.D., Ph.D.
1989-92
William Hahn, M.D., Ph.D.
1990-94
Tassie Collins, Ph.D.
1991-94
David Fruman, Ph.D.
1992-97
Kyungah K. Lee-Fruman, Ph.D.
1994-98
Hanna Yoko Irie, M.D., Ph.D.
1995-01
Michael Su, M.D., Ph.D.
1995-01
Ruben Fragoso, M.D., Ph.D.
2002-07
Saba Alzabin, Ph.D.
Graduate Student Sponsor
NYU School of Medicine
2003Yi Cai
Industry Relations
1986-96
1989-08
1990-95
1990-96
1995-00
1995,1996
1996-03
2004Leadership Roles:
1982-94
Consultant, Genetics Institute, Cambridge, MA.
Scientific Advisory Board, Vertex Pharmaceuticals,
Cambridge, MA.
Consultant, Hoffman La Roche, Basel, Switzerland.
Consultant, Medical Science Partners, Boston, MA.
Consultant, Novartis, Basel, Switzerland.
Consultant, Bristol Myers Squibb, Princeton, N.J.
Scientific Advisory Board, Pharmacopeia, Princeton, N.J.
Board of Directors, Pharmacopeia, Pharmacopeia, Princeton,
Chief of Immunology, Bone Marrow Transplant Unit, The Children's
6
1982-95
1985-00
1996-00
1996-00
1996-00
2000-07
2000-07
200720092008-
Hospital and Brigham and Women's Hospital
Director, Pediatric Oncology Research Program, Dana-Farber Cancer
Institute
Chair, Department of Pediatric Oncology, Dana-Farber Cancer Institute
Member, Executive Committee for Research, Dana-Farber Cancer Institute
Member, Board of Trustees, Dana-Farber Cancer Institute
Member, Executive Committee of the Board of Trustees, DanaFarber Cancer Institute
Director, Skirball Institute of Biomolecular Medicine, New York University
School of Medicine
Director, NYU Cancer Institute and Kaplan Comprehensive Cancer Center, New
York University School of Medicine
Director of The Tisch Cancer Institute (formerly the Mount Sinai Cancer
Institute)
Acting Chief, Division of Hematology and Medical Oncology,
Department of Medicine, Mount Sinai School of Medicine
Lillian and Henry M. Stratton Professor of Cancer Medicine,
Mount Sinai School of Medicine
C. Funding Information:
5
Past Funding:
3/1/03-2/28/08
P30 CA 016087
NIH/NCI Cancer Center Support Grant
3/1/05 – 2/20/06
Direct Amount: $1,523,650
50%
Principal Investigator: Steven J. Burakoff, M.D.
Current
Funding:
NIH
R21AI079695-01
immune response
07/15/2008
06/30/2010
Role of HPK1 in T cell mediated anti-tumor
Principal Investigator: Steven J. Burakoff, M.D.
Total amount
Year 1: 125,000
Year 2: 150,000
BIBLIOGRAPHY
Original Reports
1. Martz, E., Burakoff, S.J., and Benacerraf, B.: Interruption of the sequential release of small
and large molecules from tumor cells by low temperature during cytolysis mediated by
immune T-cells or complement. Proc. Natl. Acad. Sci. USA 1974; 71:177-181.
2.
Burakoff, S.J., Martz, E., and Benacerraf, B.: Is the primary complement lesion
insufficient for lysis? Failure of cells damaged under osmotic protection to lyse in EDTA
or at low temperature after removal of osmotic protection. Clin. Immunol. Immunopath.
1975; 4:108-126.
7
3.
Burakoff, S.J., Germain, R.N., Dorf, M.E., and Benacerraf, B.: Inhibition of cell-mediated
cytolysis of trinitrophenyl-derivatized target cells by alloantisera directed to the products
of the K and D loci of the H-2 complex. Proc. Natl. Acad. Sci. USA 1976; 73:625-629.
4.
Burakoff, S.J., Germain, R.N., and Benacerraf, B.: Cross-reactive lysis of trinitrophenyl
(TNP)-derivatized H-2 incompatible target cells by cytolytic T lymphocytes generated
against syngeneic TNP spleen cells. J. Exp. Med. 1976; 144:1609-1620.
5.
Burakoff, S.J., Dorf, M.E., and Benacerraf, B.: Specificity of rat xenogeneic cell-mediated
cytolysis for the products of the K and D loci of the mouse H-2 complex. J. Immunol.
1977; 118:1795-1798.
6.
Lemonnier, F., Burakoff, S.J., Germain, R.N., and Benacerraf, B.: Cytolytic thymusderived lymphocytes specific for allogeneic stimulator cells crossreact with chemically
modified syngeneic cells. Proc. Natl. Acad. Sci. USA 1977; 74:1229-1233.
7.
Billings, P., Burakoff, S., Dorf, M.E., and Benacerraf, B.: Cytotoxic T lymphocytes
specific for I region detererminants do not require interactions with H-2K or D gene
products. J. Exp. Med. 1977; 145:1387-1392.
8.
Billings, P., Burakoff, S., Dorf, M.E., and Benacerraf, B.: Cytotoxic T lymphocytes
induced against allogeneic I-region determinants react with Ia molecules on trinitrophenylconjugated syngeneic target cells. J. Exp. Med. 1977; 146:623-628.
9.
Burakoff, S.J., Ratnofsky, S.E., and Benacerraf, B.: Mouse cytolytic T lymphocytes
induced by xenogeneic rat stimulator cells exhibit specificity for H-2 complex
alloantigens. Proc. Natl. Acad. Sci. USA 1977; 74:4572-4576.
10. Mescher, M., Sherman, L., Lemonnier, F., and Burakoff, S.J.: The induction of secondary
cytolytic T lymphocytes by solubilized membrane proteins. J. Exp. Med. 1978; 147:946951.
11. Lemonnier, F., Mescher, M., Sherman, L., and Burakoff, S.J.: The induction of cytolytic T
lymphocytes with purified plasma membranes. J. Immunol. 1978; 120:1114-1120.
12. Lemonnier, F., Burakoff, S.J., Mescher, M., Dorf, M.E., and Benacerraf, B.: Inhibition of
the induction of cytolytic T lymphocytes with alloantisera directed against H-2K and H-2D
gene products. J. Immunol. 1978; 120:1717-1720.
13. Billings, P., Burakoff, S.J., Dorf, M.E., and Benacerraf, B.: Genetic control of cytolytic Tlymphocyte responses. I. Ir gene control of the specificity of cytolytic T lymphocyte
responses to trinitrophenyl-modified syngeneic cells. J. Immunol. 1978; 148:341-351.
14. Billings, P., Burakoff, S.J., Dorf, M.E., and Benacerraf, B.: Genetic control of cytolytic T
lymphocyte responses. II. The role of the host genotype in parental -> F1 radiation chimeras
8
in the control of the specificity of cytolytic T-lymphocyte responses to trinitrophenylmodified syngeneic cells. J. Exp. Med. 1978; 148:352-359.
15. Sherman, L.A., Burakoff, S.J., and Benacerraf, B.: The induction of cytolytic T
lymphocytes with specificity for p-azophenylarsonate coupled syngeneic cells. J.
Immunol. 1978; 121:1432-1436.
16. Finberg, R., Burakoff, S.J., Cantor, H., and Benacerraf, B.: Biological significance of
alloreactivity: T cells stimulated by Sendai virus-coated syngeneic cells specifically lyse
allogeneic target cells. Proc. Natl. Acad. Sci USA 1978; 75:5145-5149.
17. Finberg, R., Mescher, M., and Burakoff, S.J.: The induction of virus-specific cytotoxic T
lymphocytes with solubilized viral and membrane proteins. J. Exp. Med. 1978; 148:16201627.
18. Burakoff, S.J., Finberg, R., Glimcher, L., Lemonnier, F., Benacerraf, B., and Cantor, H.:
The biologic significance of alloreactivity: The ontogeny of T-cell sets specific for
alloantigens and modified self antigens. J. Exp. Med. 1978; 148:1414-1422.
19. Engelhard, V.H., Strominger, J.L., Mescher, M., and Burakoff, S.J.: Induction of
secondary cytotoxic T lymphocytes by purified HLA-A and HLA-B antigens reconstituted
into phospholipid vesicles. Proc. Natl. Acad. Sci. USA 1978; 75:5688-5691.
20. Finberg, R., Weiner, H.L., Fields, B.N., Benacerraf, B., and Burakoff, S.J.: Generation of
cytolytic T lymphocytes after retrovirus infection: Role of S1 gene. Proc. Natl. Acad. Sci.
USA 1979; 76:442-446.
21. Vadas, M.A., Butterworth, A.E., Burakoff, S., and Sher, A.: Major histocompatibility
complex products restrict the adherence of cytolytic T lymphocytes to minor
histocompatibility antigens or to trinitrophenyl determinants on schistosomula of
Schistosoma mansoni. Proc. Natl. Acad. Sci. USA 1979; 76:1982-1985.
22. Sherman, L., Mescher, M.F., and Burakoff, S.J.: The induction of cytolytic T lymphocytes
with syngeneic trinitrophenyl-coupled membranes. J. Immunol. 1979; 123:501-502.
23. Finberg, R., Greene, M.I., Benacerraf, B., and Burakoff, S.J.: The cytolytic T lymphocyte
response to trinitrophenyl-modified syngeneic cells. I. Evidence for antigen-specific helper
T cells. J. Immunol. 1979; 123:1205-1209.
24. Finberg, R., Burakoff, S.J., Benacerraf, B., and Greene, M.I.: The cytolytic T lymphocyte
response to trinitrophenyl-modified syngeneic cells. II. Evidence for antigen-specific
suppressor T cells. J. Immunol. 1979; 123:1210-1214.
25. Mescher, M.F., Finberg, R., Sherman, L., and Burakoff, S.J.: Induction of virus-specific H2 restricted murine CTL by liposomes. In: T and B lLymphocytes: Recognition and
Function. Eds, F. Bach, B. Bonavida, and E. Vitteta. Academic Press, New York, 1979;
65:623-632.
9
26. Sherman, L., Burakoff, S.J., and Mescher, M.F.: Induction of allogeneic cytolytic T
lymphocytes by partially purified membrane glycoproteins. Cell. Immunol. 1980; 51:141150.
27. Finberg, R., Cantor, H., Benacerraf, B., and Burakoff, S.J.: The origins of alloreactivity:
Differentiation of pre-killer cells to viral infection results in alloreactive cytolytic T
lymphocytes. J. Immunol. 1980; 124:1858-1860.
28. Burakoff, S.J., Engelhard, V.H., Kaufman, J., and Strominger, J.L.: Induction of secondary
cytotoxic T lymphocytes by liposomes containing HLA-DR antigens. Nature 1980;
283:495-497.
29. Abbas, A.K., Ratnofsky, S.E., and Burakoff, S.J.: T lymphocyte-mediated suppression of
myeloma function in vitro. II. Evidence for regulation of hapten-binding myelomas by
syngeneic hapten-specific cytolytic T lymphocytes. J. Exp. Med. 1980; 152:306-323.
30. Brown, A.P., Burakoff, S.J., and Sher, A.: Specificity of alloreactive T lymphocytes that
adhere to lung stage schistosomula of Schistosoma mansoni. J. Immunol. 1980; 124:25162518.
31. Engelhard, V.H., Kaufman, J.F., Strominger, J.L., and Burakoff, S.J.: Specificity of mouse
cytotoxic T lymphocytes stimulated with either HLA-aor -ß or HLA-DR antigens
reconstituted into phospholipid vesicles. J. Exp. Med. 1980; 152:54s-64s.
32. Burakoff, S.J., Riccio, J., Billings, P., Benacerraf, B., and Dorf, M.E.: Genetic control of
cytolytic T lymphocyte responses. III. The role of K and I region alleles on the specificity
of the cytolytic T lymphocyte response to trinitrophenyl-modified syngeneic cells. J.
Immunol. 1980; 125:1432-1435.
33. Abbas, A.K., Burakoff, S.J., Gefter, M.L., and Greene, M.I.: T lymphocyte-mediated
suppression of myeloma function in vitro. III. Regulation of antibody production in hybrid
myeloma cells by T lymphocytes. J. Exp. Med. 1980; 152:969-978.
34. Weinberger, O., Herrmann, S.H., Mescher, M.F., Benacerraf, B., and Burakoff, S.J.:
Cellular interactions in the generation of cytolytic T lymphocyte responses: Role of Iapositive splenic adherent cells in presentation of H-2 antigen. Proc. Natl. Acad Sci. USA
1980; 77:6091-6095.
35. Reiss, C.S., Hemler, M.E., Engelhard, V.H., Mier, J.W., Strominger, J.L., and Burakoff,
S.J.: Development and characterization of allospecific long-term human cytolytic T-cell
lines. Proc. Natl. Acad. Sci. USA 1980; 77:5432-5436.
36. Burakoff, S.J., Weinberger, O., Herrmann, S.H., and Mescher, M.F.: The use of purified
H-2 antigens to define the helper T cell pathway involved in cytolytic T lymphocyte
induction. Behring Inst. Mitt. 1980; 67:118-122.
10
37. Finberg, R., Weiner, H.L., Burakoff, S.J., and Fields, B.N.: Type-specific reovirus
antiserum blocks the cytotoxic T cell/target cell interaction: Evidence for the association of
the viral hemagglutinin of a nonenveloped virus with the cell surface. Inf. and Imm. 1981;
31:646-649.
38. Burakoff, S.J., Weinberger, O., Herrmann, S.H., and Mescher, M.F.: Cellular interactions
in the regulation of the cytolytic T-lymphocyte response: The effect of suboptimal antigen
dose. Transplant. Proc. 1981; 13:1039-1043.
39. Weinberger, O., Herrmann, S., Mescher, M.F., Bennacerraf, B., and Burakoff, S.J.:
Cellular interactions in the generation of cytolytic T lymphocyte responses. Analysis of
the helper T cell pathway. Eur. J. Immunol. 1981; 11:405-411.
40. Weinberger, O., Herrmann, S., Mescher, M.F., Benacerraf, B., and Burakoff, S.J.:
Antigen-presenting cell function in induction of helper T cells for cytotoxic T lymphocyte
responses: Evidence for antigen processing. Proc. Natl. Acad. Sci. USA 1981; 78:17961799.
41. Reiss, C.S., and Burakoff, S.J.: Specificity of the helper T cell for the cytolytic T
lymphocyte response to influenza viruses. J. Exp. Med. 1981; 154:541
42. Reiss, C.S., Dorf, M.E., Benacerraf, B., and Burakoff, S.J.: Ir gene control of the cytolytic
T cell response to influenza virus. In: Genetic Variation Among Influenza Viruses. Ed.,
D.P. Nayak. Academic Press, New York, 1981; 449-459.
43. Shapiro, M.E., Burakoff, S.J., Benacerraf, B., and Finberg, R.W.: Ir gene control of the
cytotoxic T lymphocyte response to Sendai virus: H-2k mice are low responders to Sendai.
J. Immunol. 1981; 127:2571-2574.
44. Gualde, N., Weinberger, O., Ratnofsky, S., Benacerraf, B., and Burakoff, S.J.: In vitro
generation of helper T cells and suppressor T cells that regulate the cytolytic T lymphocyte
response to trinitrophenyl modified syngeneic cells. Transplantation 1982; 33:422-427.
45. Greene, M.I., Ratnofsky, S., Takaoki, M., Sy, M.S., Burakoff, S.J., and Finberg, R.W.:
Antigen-specific suppression of cytotoxic T cell responses: An idiotype-bearing factor
regulates the cytotoxic T cell response to azobenzenearsonate-coupled cells. J.Immunol.
1982; 128:1188-1191.
46. Herrmann, S.H., Weinberger, O., Burakoff, S.J., and Mescher, M.F.: Analysis of the twosignal requirement for precursor cytolytic T lymphocyteactivation using H-2Kk in
liposomes. J. Immunol. 1982; 128:1968-1974.
47. Reiss, C.S., Dorf, M.E., Benacerraf, B. and Burakoff, S.J.: Genetic control of the cytolytic
T lymphocyte response to influenza viruses: H-2D genes influence the response to H-2Kb
plus virus. J. Immunol. 1982; 128:2295-2299.
11
48. Krensky, A.M., Reiss, C.S., Mier, J.W., Strominger, J.L., and Burakoff, S.J: Long-term
human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. Proc. Natl.
Acad. Sci. USA 1982; 79:2365-2369.
49. Moser, G., Burakoff, S.J., and Abbas, A.K.: Suppression of anti-hapten antibody responses
by hapten-specific cytolytic T lymphocytes: Role of I-A-associated antigen on target B
lymphocytes. J. Immunol. 1982; 129:6369.
50. Weinberger, O., Germain, R.N., Springer, T., and Burakoff, S.J.: Role of syngeneic Ia +
accessory cells in the generation of allospecific CTL responses. J. Immunol. 1982;
129:694-697.
51. Krensky, A.M., Ault, K.A., Reiss, C.S., Strominger, J.L., and Burakoff, S.J.: Generation of
long-term human cytolytic cell lines with persistent natural killer activity. J. Immunol.
1982; 129:1748-1751.
52. Duprez, V., Hamilton, B., and Burakoff, S.J.: Generation of cytolytic T lymphocytes in
thymectomized, irradiated, and bone marrow-reconstituted mice. J. Exp. Med. 1982;
156:844-859.
53. Krensky, A.M., Clayberger, C., Reiss, C.S., Strominger, J.L., and Burakoff, S.J.:
Specificity of OKT4+ cytotoxic T lymphocyte clones. J. Immunol. 1982; 129:2001-2005.
54. Sanchez-Madrid, F., Krensky, A.M., Ware, C.F., Robbins, E., Strominger, J.L., Burakoff,
S.J., and Springer, T.A.: Three distinct antigens associated with human T lymphocytemediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc. Natl. Acad. Sci. USA 1982;
79:7489-7493.
55. Duprez, V., Mescher, M.F., and Burakoff, S.J.: Stimulation of secondary anti-MSV
cytolytic T lymphocytes with MBL-2 reconstituted membranes. J. Immunol. 1983;
130:493-495.
56. Weinberger, O., Germain, R.N., and Burakoff, S.J.: Responses to the H-2Kba mutant
involve recognition of syngeneic Ia molecules. Nature 1983; 302:429-431.
57. Reiss, C.S., Evans, G.A., Margulies, D.H., Seidman, J.G. and Burakoff, S.J.: Allospecific
and virus-specific cytolytic T lymphocytes are restricted to the N and C1 domain of H-2
antigens expressed on L cells after DNA-mediated gene transfer. Proc. Natl. Acad. Sci.
USA 1983; 80:2709-2712.
58. Pober, J.S., Gimbrone, M.A., Jr., Cotran, R.S., Reiss, C.S., Burakoff, S.J., Fiers, W., and
Ault, K.A.: Ia expression by vascular endothelium is inducible by activated T cells and by
human -interferon. J. Exp. Med. 1983; 157:1339-1353.
59. Ben-Nun, A., Lando, Z., Dorf, M.E., and Burakoff, S.J.: Analysis of cross-reactive
antigen-specific T cell clones: Specific recognition of two major histocompatibility
complex (MHC) and two non-MHC antigens by a single clone. J. Exp. Med. 1983;
12
157:2147-2153.
60. Krensky, A.M., Sanchez-Madrid, F., Robbins, E., Nagy, J.A., Springer, T.A., and
Burakoff, S.J.: The functional significance, distribution, and structure of LFA-1, LFA- 2,
and LFA-3: Cell surface antigens associated with CTL-target interactions. J. Immunol.
1983; 131:611-616.
61. Ware, C.F., Sanchez-Madrid, F., Krensky, A.M., Burakoff, S.J., Strominger, J.L., and
Springer, T.A.: Human lymphocyte function associated antigen-1 (LFA-1): Identification
of multiple antigenic epitopes and their relationship to CTL-mediated cytotoxicity. J.
Immunol.1983; 131:1182-1188.
62. Flyer, D.C., Burakoff, S.J., and Faller, D.V.: Cytotoxic T lymphocyte recognition of
transfected cells expressing a cloned retroviral gene. Nature 1983; 305:815-818.
63. Ware, C.F., Krangel, M.S., Pious, D., Burakoff, S.J., and Strominger, J.L.: Recognition of
HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T
lymphocyte line. J. Immunol. 1983; 131:1312-1317.
64. Pober, J.S., Collins, T., Gimbrone, M.A., Jr., Cotran, R.S., Gitlin, J.D., Fiers, W.,
Clayberger, C., Krensky, A.M., Burakoff, S.J., and Reiss, C.S.: Lymphocytes recognize
human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant
immune interferon. Nature 1983; 305:726-729.
65. Krensky, A.M., Clayberger, C., Greenstein, J.L., Crimmins, M., and Burakoff, S.J.: A DCspecific cytolytic T lymphocyte line is OKT8+. J. Immunol. 1983; 131:2777-2780.
66. Murre, C., Reiss, C.S., Bernabeu, C., Chen, L.B., Burakoff, S.J., and Seidman, J.G.:
Construction, expression and recognition of an H-2 molecule lacking its carboxyl
terminus. Nature 1984; 307:432-436.
67. Duprez, V., Maziarz, R., Weinberger, O., and Burakoff, S.J.: Thymectomized, irradiated,
and bone marrow reconstituted chimeras have normal cytolytic T lymphocyte precursors
but a defect in lymphokine production. J. Immunol. 1984; l32:2185-2189.
68. Greenstein, J.L., Kappler, J., Marrack, P., and Burakoff,S.J.: The role of L3T4 in
recognition of Ia by a cytotoxic, H-2Dd-specific T cell hybridoma. J. Exp. Med. 1984;
159:1213-1224.
69. Krensky, A.M., Robbins, E., Springer, T.A., and Burakoff, S.J.: LFA-1, LFA-2, and LFA3 antigens are involved in CTL-target conjugation. J. Immunol. 1984; 132:2180-2182.
70. Hemler, M.E., Sanchez-Madrid, F., Flotte, T.J., Krensky, A.M., Burakoff, S.J., Bhan,
A.K., Springer, T.A., and Strominger, J.L.: Glycoproteins of 210,000 and 130,000 M.W.
on activated T cells: Cell distribution and antigenic relation to components on resting cells
and T cell lines. J. Immunol. 1984; 132:3011-3018.
13
71. Greenberger, J.S., Krensky, A.M., Messner, H., Burakoff, S.J., Wandl, U., and Sakakeeny,
M.A.: Production of colony-stimulating factor(s) for granulocyte-macrophage and
multipotential
(granulocyte/erthroid/megakaryocyte
/macrophage)
hematopoietic
progenitor cells (CFU-GEMM) by clonal lines of human IL-2-dependent T-lymphocytes.
Exp. Hematol. 1984; 12:720-727.
72. Collins, T., Krensky, A.M., Clayberger, C., Fiers, W., Gimbrone, M.A., Jr., Burakoff, S.J.,
and Pober, J.S.: Human cytolytic T lymphocyte interactions with vascular endothelium and
fibroblasts: Role of effector and target cell molecules. J. Immunol. 1984; 133:1878-1884.
73. Murre, C., Choi, E., Weis, J., Seidman, J.G., Ozato, K., Liu, L., Burakoff, S.J., and Reiss,
C.S.: Dissection of serological and cytolytic T lymphocyte epitopes on murine major
histocompatibility antigens by a recombinant H-2 gene separating the first two external
domains. J. Exp. Med. 1984; 160:167-178.
74. Stallcup, K.C., Burakoff, S.J., and Mescher, M.F.: Inhibition of normal lymphocyte
responses by cell membranes. Cell. Immunol. 1984; 89:144-150.
75. Barbosa, J.A., Mentzer, S.J., Minowada, G., Strominger, J.L., Burakoff, S.J., and Biro,
P.A.: Recognition of HLA-A2 and -B7 antigens by cloned cytotoxic T lymphocytes after
gene transfer into human and monkey, but not mouse, cells. Proc. Natl. Acad. Sci. USA
1984; 81:7549-7553.
76. Stallcup, K.C., Burakoff, S.J., and Mescher, M.F.: Growth-inhibitory activity of lymphoid
cell plasma membranes. II. Partial characterization of the inhibitor. J. Cell. Biol. 1984;
99:1227-1234.
77. Bernabeu, C., Maziarz, R., Spits, H., de Vries, J., Burakoff, S.J., and Terhorst, C.:
Coexpression of the human HLA-A2 or HLA-B7 heavy chain gene and human B2microglobulin gene in L cells. J. Immunol. 1984; 133:3188-3194.
78. Miller, B.A., Lipton, J.M., Linch, D.C., Burakoff, S.J., and Nathan, D.G.: Thy-l is a
differentiation antigen that characterizes immature murine erythroid and myeloid
hematopoietic progenitors. J. Cell. Physiol.1985; 123(1)25-32.
79. Gromkowski, S.H., Krensky, A.M., Martz, E., and Burakoff, S.J.: Functional distinctions
between the LFA-l, LFA- 2, and LFA-3 membrane proteins on human CTL are revealed
with trypsin-pre-treated target cells. J. Immunol. 1985; 134:244-249.
80. O'Flynn, K., Krensky, A.M., Beverley, P.C.L., Burakoff, S.J., and Linch, D.C.:
Phytohaemagglutinin activation of T-cells through the sheep red blood cell receptor.
Nature 1985; 313:686-687.
81. Umetsu, D.T., Pober, J.S., Jabara, H.H., Fiers, W., Yunis, E.J., Burakoff, S.J., Reiss, C.S.,
and Geha, R.S.: Human dermal fibroblasts present tetanus toxoid antigen to antigenspecific T cell clones. J. Clin. Invest. 1985; 76:254-260.
14
82. Weis, J.H., Reiss, C.S., Mulligan, R.C., Burakoff, S.J., and Seidman, J.G.: H-2Ld antigen
encoded by a recombinant retrovirus genome is expressed on the surface of infected cells.
Mol. Cell. Biol. 1985; 5:1379-1384.
83. Mentzer, S.J., Gromkowski, S.H., Krensky, A.M., Burakoff, S.J., and Martz, E.: FA-1
membrane molecule in the regulation of homotypic adhesions of human B lymphocytes. J.
Immunol. 1985; 135:9-11.
84. Mentzer, S.J., Barbosa, J.A., and Burakoff, S.J.: T3 monoclonal antibody activation of
nonspecific cytolysis: A mechanism of CTL inhibition. J. Immunol. 1985; 135:34-38.
85. Greenstein, J.L., Malissen, B., and Burakoff, S.J.: Role of L3T4 in antigen-driven
activation of a lass I-specific T cell hybridoma. J. Exp. Med. 1985; 162:369-374.
86. Weinberger, O., Herrmann, S.H., Greenstein, J.L., Mescher, M.F., and Burakoff, S.J.: The
ability of Ia and H-2Kk bearing membranes to replace the antigen-presenting cell in an H2Kk allogeneic cytotoxic T cell response. Eur. J. Immunol. 1985; 15:1013-1018.
87. Maziarz, R., Allen, H., Strominger, J.L., Flavell, R., Biro, P.A., and Burakoff, S.J.:
Recognition of inter-species hybrid class I histocompatibility antigens by antigen-specific
cytolytic T lymphocytes. Proc. Natl. Acad. Sci. 1985; 82:6276-6280.
88. Flyer, D.C., Burakoff, S.J., and Faller, D.V.: Retrovirus- induced changes in major
histocompatibility complex antigen expression influence susceptibility to lysis by
cytotoxic T lymphocytes. J. Immunol. 1985; 135:2287-2292.
89. Heilig, J.S., Glimcher, L.H., Kranz, D.M., Clayton, L.K., Greenstein, J.L., Saito, H.,
Maxam, A.M., Burakoff, S.J., Eisen, H.N., and Tonegawa, S.: Expression of the T cellspecific gamma gene is unnecessary in T cells recognizing class II MHC determinants.
Nature 1985; 317:68-70.
90. Krensky, A.M., Mentzer, S.J., Clayberger, C., Anderson, D.C., Schmalstieg, F.C.,
Burakoff, S.J., and Springer, T.A.: Heritable lymphocyte function-associated antigen- 1
deficiency: Abnormalities of cytotoxicity and proliferation associated with abnormal
expression of LFA-1. J. Immunol. 1985; 135:3102-3108.
91. Bernabeu, C., Maziarz, R., Burakoff, S., and Terhorst, C.: Beta-2 microglobulin from
serum associates with several class I antigens expressed on the surface of mouse L cells.
Mol. Immunol. 1985; 22:955-960.
92. Murre, C., Parker, K.C., Reiss, C.S., Driller, J.P., Wiley, D.C., Burakoff, S.J., and
Seidman, J.G.: Biochemical and functional analyses of a secreted H-2Ld molecule. Mol.
Cell. Immunol. 1986; 6:1315-1319.
93. Mentzer, S.J., Burakoff, S.J., and Faller, D.V.: Adhesion of T lymphocytes to human
15
endothelial cells is regulated by the LFA-1 membrane molecule. J. Cell. Physiol. 1986;
126:285-290.
94. Reiss, C.S., Greenstein, J.L., Crimmins, M.A.V., Liu, L.L.M., Rao, A., Maziarz, R.T.,
Murre, C., and Burakoff, S.J.: Recognition of the a-l and a-2 domains of H-2 molecules by
allospecific cloned T cells. J. Immunol. 1986; 136:2191-2194.
95. Maziarz, R.T., Burakoff, S.J., and Reiss, C.S.: Viral restricted cytolytic T lymphocyte
recognition of hybrid human-murine class I histocompatibility antigens. Cell. Immunol.
1986;99: 279-286.
96. Ferrara, J., Guillen, F.J., Sleckman, B., Burakoff, S.J., and Murphy, G.F.: Cutaneous acute
graft-versus-host disease to minor histocompatibility antigens in a murine model:
Histologic analysis and correlation to clinical disease. J. Invest. Derm. 1986; 86:371-375.
97. Greenstein, J.L., Foran, J.A., Gorga, J.C., and Burakoff, S.J.: The role of T cell accessory
molecules in the generation of class II-specific xenogeneic cytolytic T cells. J. Immunol.
1986; 136:2358-2363.
98. Guillen, F.J., Ferrara, J., Hancock, W.W., Messadi, D., Fonferko, E., Burakoff, S.J., and
Murphy, G.F.: Acute cutaneous graft-versus-host disease to minor histocompatibility
antigens in a murine model: Evidence that large granular lymphocytes are effector cells in
the immune response. J. Lab. Invest. 1986; 55:35-42.
99. Rozans, M.K., Smith, B.R., Emerson, S., Crimmins, M., Laurent, G., Reichert, T.,
Burakoff, S.J., and Miller, R.A.: Functional assessment of T cell depletion from bone
marrow prior to therapeutic transplantation using limiting dilution culture methods.
Transplant. 1986; 42:380-387.
100. Barbosa, J.A., Mentzer, S.J., Kamarck, M.E., Hart, J., Biro,P.A., Strominger, J.L., and
Burakoff, S.J.: Gene mapping and somatic cell hybrid analysis of the role of human
lymphocyte function-associated antigen-3 (LFA-3) in CTL-target cell interactions. J.
Immunol. 1986; 136:3085-3091.
101. Greenstein, J.L., Herrmann, S.H., Sunshine, G.H., and Burakoff, S.J.: The mechanism of
antigen presentation by dendritic cells and splenic adherent cells in the induction of an
allogeneic cytotoxic T-lymphocyte response to H-2Kk lysosomes. Cell. Immunol. 1986;
100:389-399.
102. Rozans, M.K., Smith, B.R., Burakoff, S.J., and Miller, R.A.: Long-lasting deficit of
functional T cell precursors in human bone marrow transplant recipients revealed by
limiting dilution methods. J. Immunol. 1986; 136:4040-4048.
103. Mentzer, S.J., Krensky, A.M., and Burakoff, S.J.: Mapping functional epitopes of the
human LFA-1 glycoprotein: Monoclonal antibody inhibition of NK and CTL effectors.
Human Immunol. 1986; 17:288-296.
16
104. Mentzer, S.J., Faller, D.V., and Burakoff, S.J.: Interferon-y induction of LFA-1-mediated
homotypic adhesion of human monocytes. J. Immunol. 1986; 137:108-113.
105. Mentzer, S.J., Guyre, P.M., Burakoff, S.J., and Faller, D.V.: Spontaneous aggregation as a
mechanism for human monocyte purification. Cell. Immunol. 1986; 101:312-319.
106. Mentzer, S.J., Barbosa, J.A., Strominger, J.L., Biro, P.A., and Burakoff, S.J.: Speciesrestricted recognition of transfected HLA-A2 and HLA-B7 by human CTL clones. J.
Immunol. 1986; 137:408-413.
107. Ferrara, J.L.M., Marion, A., McIntyre, J.F., Murphy, G.F., and Burakoff, S.J.:
Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in
vivo administration of anti-Interleukin 2 receptor antibody. J. Immunol. 1986; 137:1874-7.
108. Gorga, J.C., Knudsen, P.J., Foran, J.A., Strominger, J.L., and Burakoff, S.J.:
Immunochemically purified DR antigens in liposomes stimulate xenogeneic cytolytic T
cells in secondary in vitro cultures. Cell. Immunol. 1986; 103:160-173.
109. Takai, Y., Herrmann, S.H., Greenstein, J.L., Spitalny, G.L., and Burakoff, S.J.:
Requirement for three distinct lymphokines for the induction of cytotoxic T lymphocytes
from thymocytes. J. Immunol. 1986; 137:3494-3500.
110. Sung, K-L.P., Sung, L.A., Crimmins, M., Burakoff, S.J., and Chien, S.: Determination
ofjunction avidity of cytolytic T cell and target cell. Science 1986; 234:1405-1408.
111. Ferrara, J., Lipton, J., Hellman, S., Burakoff, S.J., and Mauch, P.: Engraftment following T
cell-depleted marrow transplantation. I. The role of major and minor histocompatibility
barriers. Transplant. 1987; 43:461-467.
112. Maziarz, R.T., Fraser, J., Strominger, J.L., and Burakoff, S.J.: The human HLA-specific
monoclonal antibody W6/32 recognizes a discontinuous epitope within the alpha-2 domain
of murine H-2Db. Immunogenet. 1986; 24:206-208.
113. Mentzer, S.J., Bierer, B.E., Anderson, D.C., Springer, T.A., and Burakoff, S.J.: Abnormal
cytolytic activity of LFA- 1 deficient human CTL clones. J. Clin. Invest. 1986; 78:13871391.
114. Mentzer, S.J., Smith, B.R., Barbosa, J.A., Crimmins, M.A.V., Herrmann, S.H., and
Burakoff, S.J.: CTL adhesion and antigen recognition are discrete steps in the human CTLtarget cell interaction. J. Immunol.1987; 138:1325-1330.
115. Mentzer, S.J., Remold-O'Donnell, E., Crimmins, M.A.V., Bierer, B.E., Rosen, F.S., and
Burakoff, S.J.: Sialophorin, a surface sialoglycoprotein defective in the Wiskott-Aldrich
Syndrome, is involved in human T lymphocyte proliferation. J. Exp. Med. 1987;
165:1383-1392.
17
116. Ferrara, J.L.M., Daley, J.P., Burakoff, S.J., and Miller, R.A.: Functional T cell deficits
after bone marrow transplantation across minor histocompatibility barriers: Effects of
Graft-vs-Host Disease on precursor frequency of reactive cells. J. Immunol. 1987;
138:3598-3603.
117. Ferrara, J.L.M., Mauch, P., McIntyre, J., Michaelson, J., and Burakoff, S.J.: Engraftment
following T cell depleted bone marrow transplantation. II. Stability of mixed chimerism in
semisyngeneic recipients after total body irradiation. Transplant. 1987; 44:495-499.
118. Rosoff, P.M., Burakoff, S.J., and Greenstein, J.L.: The role of the L3T4 molecule in
mitogen and antigen- activated signal transduction. Cell 1987; 49:845-853.
119. Mentzer, S.J., Crimmins, M.A.V., Burakoff, S.J., and Faller, D.V.: Alpha and beta
subunits of the LFA-1 membrane molecule are involved in human monocyte-endothelial
cell adhesion. J. Cell. Physiol. 1987; 130:410-415.
120. Bierer, B.E., Herrmann, S.H., Brown, C.S., Burakoff, S.J., and Golan, D.E.: Lateral
mobility of class I histocompatibility antigens in B lymphoblastoid cell membranes:
Modulation by cross-linking and effect of cell density. J. Cell. Biol. 1987; 105: 1147-1152.
121. Sleckman, B.P., Peterson, A., Jones, W.K., Foran, J.A., Greenstein, J.L., Seed, B., and
Burakoff, S.J.: Expression and function of CD4 in a murine T cell hybridoma. Nature.
1987; 328:351-353.
122. Takai, Y., Reed, M.L., Burakoff, S.J., and Herrmann, S.H.: Direct evidence for a receptorligand interaction between CD2 and LFA-3. Proc. Natl. Acad. Sci. USA.1987; 84:68646868.
123. Nishimura, T., Burakoff, S.J., Herrmann, S.H.: Protein kinase C required for cytotoxic T
lymphocyte triggering. J. Immunol. 1987; 139:2888-2891.
124. Takai, Y., Wong, G.G., Clark, S.C., Burakoff, S.J., and Herrmann, S.H.: B-cell stimulatory
factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J. Immunol. 1988;
140:508-512.
125. Kinsey B.M., Macklis R.M., Ferrara J.L.M., Layne W.W., Burakoff, S.J. and Kassis, A.I.:
Efficient conjugation of DTPA to an IgM monoclonal antibody in acites fluid. Nuc. Med.
Biol. 1988; 15:285-292.
126. Ratnofsky, S.E., Peterson, A., Greenstein, J.L., and Burakoff, S.J.: Expression and function
of CD8 in a murine T cell hybridoma. J. Exp. Med. 1987; 166:1747-1757.
127. Bierer, B.E., Peterson, A., Barbosa, J., Seed, B., and Burakoff, S.J.: Expression of the Tcell surface molecule CD2 and an epitope loss CD2 mutant to define the role of
Lymphocyte fuction-associated antigen-3 (LFA-3) in T cell activation. Proc. Natl. Acad.
18
Sci. USA. 1988; 85:1194-1198.
128. Barbosa, J.A., Santos-Aguado, J., Mentzer, S.J., Strominger, J.L., Burakoff, S.J., and Biro,
P.A.: Site-directed mutagenesis of class I HLA genes. Role of glycosylation in surface
expression and functional recognition. J. Exp. Med. 1987; 166:1329-1350.
129. Bierer, B.E., Nishimura, Y., Burakoff, S.J., and Smith, B.R.: Functional and phenotypic
characterization of T cells lacking expression of CD5. J. Clin. Invest. 1988; 81:13901397.
130. Ferrara, J.L.M., Michaelson, J., Burakoff, S.J., and Mauch, P.: Engraftment following T
cell-depleted bone marrow transplantation. III. Differential effects of increased total-body
irradiation on semiallogeneic and allogeneic recipients. Transplant. 1988; 45:948-952.
131. Macklis, R. M., Kaplan, W. D., Ferrara, L. M., Kinsey B. M., Kassis, A. I., Burakoff, S.J.:
Biodistribution studies of Anti-Thy 1.2 IgM immunoconjugates: Implications for
Radioimmunotherapy. Int. J. Radiation Oncology Biol. Phys. 1988; 15:383-389.
132. Nishimura Y., Bierer B.E., Jones W., Jones N., Strominger J.L., and Burakoff S.J.:
Expression and function of a CD5 cDNA in human and murine T cells. Eur. J. Immunol.
1988; 18:747-753.
133. Bierer, B.E., Barbosa, J., Herrmann, S., Burakoff, S.J.: The interaction of CD2 with its
ligand, LFA-3, in human T cell proliferation, J. Immunol. 1988; 140:3358-3363.
134. Macklis, R.M., Kinsey, B.M., Kassis, A.I., Ferrara, J.L.M., Atcher, R.W., Hines, J.J.,
Coleman, C.N., Adelstein, S.J., Burakoff, S.J.: Radioimmunotherapy with alpha particleemitting immunoconjugates. Science 1988; 240:1024-1026.
135. Daley, J.P., Rozans, M.K., Smith, B.R., Burakoff, S.J., Rappeport, J.M., and Miller, R.A.:
Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow
transplant recipients. Blood 1987; 70:960-964.
136. Maziarz, R.T., Burakoff, S.J., and Bluestone, J.A.: The a-3 domain of class I MHC
proteins influences cytotoxic T lymphocyte recognition of antigenic determinants located
within the a-1 and a-2 domains. J. Immunol. 1988; 140:4372-4377.
137. Sleckman, B.P., Peterson, A., Foran, J.A., Gorga, J.C., Kara, C.J., Strominger, J.L.,
Burakoff, S.J. and Greenstein, J.L.: Functional analysis of a cytoplamic domain deleted
mutant of the CD4 molecule. J. Immunol. 1988; 141:49-54.
138. Mentzer, S.J., Herrmann, S.H., Crimmins, M.A.V., Burakoff, S.J., and Faller, D.V. The
role of CD18 in Phorbol Ester-induced human monocyte-mediated cytotoxicity. Cell.
Immunol. 1988;115:66-77.
139. Bierer, B.E., Emerson, S.G., Antin, J., Maziarz, R., Rappeport, J.M., Smith, B.R.,
19
Burakoff, S.J.: Regulation of cytotoxic T lymphocytes-mediated graft rejection following
bone marrow transplantation. Transplant. 1988; 46:835-839.
140. Bierer, B.E., Peterson, A. Gorga, J.C., Seed, B., Herrmann, S.H., Burakoff, S.J.:
Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor.
J. Exp. Med. 1988; 168:1145-1156.
141. Nishimura, Y., Bierer, B.E. and Burakoff, S.J.: Expression of CD5 regulates
responsiveness to interleukin 1. J. Immunol. 1988; 141:3438-3444.
142. Diamond, D.C., Sleckman, B.P., Gregory, T., Lasky, L.A., Greenstein, J.L. and Burakoff,
S.J.: Inhibition of CD4+ T cell function by the HIV envelope protein gp120. J. Immunol.
1988; 141:3715-3717.
143. Kuo-Li. P.S., Lanping, A., Crimmens, M., Burakoff, S.J., and Chien, S.: Dynamic changes
in visoelastic properties in cytotoxic T lymphocyte-mediated killing. J. Cell. Science 1988;
91:179-189.
144. Petrarca, M.A., Reiss, C., Diamond, D., Boni, J., Burakoff, S.J. and Faller, D.: T cell
hybridomas define the class II MHC-restricted response to vesicular stomatitis virus
infection. Microbial Pathogenesis 1988; 5:319-332.
145. Wall, D.A., Hamberg, S.D., Reynolds, D.S., Burakoff, S.J., Abbas, A.K., Ferrara, J.L.M.:
Immunodeficiency in graft versus host disease. 1. Mechanism of immune suppression. J.
Immunol. 1988; 140:2970-2976.
146. Rosenstein, Y., Ratnofsky, S., Burakoff, S.J. and Herrmann, S.H.: Direct evidence for
binding CD8 to HLA class I antigen. J. Exp. Med. 1989; 169:149-160.
147. Stringfellow, M., Wilson, R., Burakoff, S.J., and Herrman, S.H.: Effect of timing of
lymphokine presentation on generation of cytotoxic T lymphocytes. Arch. Surg. 1989;
124:81-84.
148. Bierer, B., Burakoff, S.J., and Smith, B.: A large proportion of T lymphocytes lack CD5
expression following allogeneic bone marrow transplantation. Blood 1989; 73:1359-1366.
149. Sleckman, B., Bigby, M., Greenstein, J.L., Burakoff, S.J. and Sun Sy, M.: Requirements
for modulation of the CD4 molecule in response to PMA: Role of the cytoplasmic domain.
J. Immunol. 1989; 142:1457-1462.
150. Bierer, B.E., Golan, D., Brown, C., Herrmann, S., and Burakoff, S.J.: A monoclonal
antibody to LFA-3, the CD2 ligand, specifically immobilizes major histocompatability
complex proteins. Eur. J. Immunol. 1989; 19:661-665.
151. Nishimura, T., Burakoff, S.J., and Herrmann, S.H.: Inhibition of lymphokine-activated
killer cell-mediated cytotoxicity by phorbol ester. J. Immunol. 1989; 142:2155-2161.
20
152. Sen, J., Arceci, R.J., Jones, W. and Burakoff, S.J.: Expression and ontogeny of murine
CD2. Eur. J. Immunol. 1989; 19:1297-1302.
153. Maziarz, R.T., Burakoff, S.J., and Faller, D.V.: The regulation of exogenous and
endogenous class I MHC genes in a human tumor cell line, K562. Mol. Immunol. 1990;
27:135-142.
154. Ferrara, J.L.M., Guillen, F.J., van Dijken, P.J., Marion, A., Murphy, G.F., and Burakoff,
S.J.: Evidence that large granular lymphocytes of donor origin mediate acute graft-versushost disease. Transplant. 1989; 47:50-54.
155. Mittler, R.S., Goldman, S.J., Spitalny, G.L., and Burakoff, S.J.: T cell receptor-CD4
physical association in a murine T cell hybridoma: Induction by antigen receptor ligation.
Proc. Natl. Acad. Sci. USA 1989; 86:8531-8535.
156. Groh, V., Fabbi, M., Maziarz R., Hochstenbach, F., Burakoff, S.J., and Strominger, J.L.:
"Double negative" (CD4-CD8-) lymphocytes bearing T-cell receptor  and ß chains in
normal human skin. Proc. Natl. Acad. Sci. USA 1989; 86:5059-5063.
157. Santos-Aguado, J., Crimmens, M.A.V., Mentzer, S.J., Burakoff, S.J., and Strominger, J.L.:
Alloreactivity studied with mutants of HLA-A2. Proc. Natl. Acad. Sci. USA 1989;
86:8936-8940.
158. van Dijken, P.J., Ghayur, T., Mauch, P., Down, D., Burakoff, S.J., Ferrara, J.L.M.:
Evidence that anti-LFA-1 in vivo improves engraftment and survival after allogeneic bone
marrow transplantation. Transplant. 1990; 49:882-886.
159. Ferrara, J.L.M., Mauch, P., van Dijken, P.J., Crosier, K.E., Michaelson, J., Burakoff, S.J.:
Anti-asialo GM1 in vivo improves engraftment of T cell depleted bone marrow in hybrid
recipients. Transplant. 1990; 49:134-138.
160. Veillette, A., Sleckman, B.P., Ratnofsky, S., Bolen, J.B., and Burakoff, S.J.: The
cytoplasmic domain of CD4 is required for stable association with the lymphocyte-specific
tyrosine protein kinase p56lck. Eur. J. Immunol. 1990; 20:1397-1170.
161. Bierer, B.E., Schreiber, S.L., Burakoff, S.J.: Mechanism of immunosuppression by FK506:
preservation of T cell transmembrane signal transduction. Transplant. 1990; 49:1168-1170.
162. Bierer, B.E., Bogart, R., and Burakoff, S.J.: Partial deletions of the cytoplasmic domain of
CD2 result in a partial defect in signal transduction. J. Immunol. 1990; 144:785-789.
163. Rosenstein, Y., Burakoff, S.J., and Herrmann, S.H.: HIV-gp120 can block CD4-class II
MHC-mediated adhesion. J. Immunol. 1990; 144:526-531.
164. Diamond, D.C., Finberg, R., Chaudhuri, S., Sleckman, B.P., and Burakoff, S.J.: Human
immunodeficiency virus infection is efficiently mediated by a glycolipid anchored form of
CD4. Proc. Natl. Acad. Sci. USA 1990; 87:5001-5005.
21
165. Wolff, H.L., Burakoff, S.J., and Bierer, B.E.: Functional CD2 mutants unable to bind to, or
be stimulated by, LFA-3. J. Immunol. 1990; 144:1215-1220.
166. Sen, J., Rosenberg, N. and Burakoff, S.J.: Expression and ontogeny of CD2 on murine B
cells. J. Immunol. 1990; 144:2925-2930.
167. Finberg, R.W., Diamond, D., Mitchell, M., Rosenstein, Y., Soman, G., Norman, T.C.,
Schreiber, S.L., Burakoff, S.J.: Prevention of HIV-1 infection and preservation of CD4
function by the binding of CPFs to gp120. Science 1990; 249:287-291.
168. Bierer, B.E., Mattila, P.S., Standaert, R.F., Herzenberg, L.A., Burakoff, S.J., Crabtree, G.,
Schreiber, S.L: Two distinct signal transmission pathways in T lymphocytes are inhibited
by alternative complexes formed between an immunophilin and either FK506 or
rapamycin. Proc. Natl. Acad. Sci. USA 1990; 87:9231-9235.
169. Bierer, B.E., Somers, P.K., Wandless, T.J., Burakoff, S.J., Schreiber, S.L.: Probing
immunosuppressant action with a nonnatural immunophilin ligand. Science 1990;
250:556-559.
170. Bowman, M.R., MacFerrin, K.D., Schreiber, S.L., and Burakoff, S.J.: Identification and
structural analysis of residues in the V1 region of CD4 involved in the interaction with
HIV gp120 and class II MHC. Proc. Natl. Acad. Sci. USA 1990; 87:9052-9056.
171. Maziarz, R.T., Mentzer, S.J., Burakoff, S.J., and Faller, D.V.: Distinct effects of
interferon- and MHC class I surface antigen levels on resistance of the K562 tumor cell
line to natural killer-mediated lysis. Cell. Immunol. 1990; 130:329-338.
172. Bierer, B.E., Schreiber, S.L., Burakoff, S.J.: The effect of the immunosuppressant FK506
on alternate pathways of T cell activation. Eur. J. Immunol. 1991; 21:439-445.
173. Fretz, H., Albers, M.W., Galat, A., Standaert, R.F., Lane, W.S., Burakoff, S.J., Bierer,
B.E., and Schreiber, S.L.: Rapamycin and FK506 binding proteins (Immunophilins). J.
Am. Chem. Soc. 1991; 113:1409-1411.
174. Sekaly, R-P., Crouteau, G., Bowman, M., Scholl, P., Burakoff, S.J., and Geha, R.S.: The
CD4 molecule is not always required for the T cell response to bacterial enterotoxins. J.
Exp. Med. 1991; 173:367-371.
175. Rimm, I.J., Ghayur, T., Gasser, D.L., Rosenkrantz, K., Burakoff, S.J., Seidman, J.G., and
Ferrara, J.L.M.: Alloreactive lymphocytes from T cell receptor (ß chain) transgenic mice
do not mediate a graft-versus-host reaction. J. Immunol. 1991; 146:1130-1133.
176. Jin, Y-J., Albers, M.W., Lane, W.S., Bierer, B.E., Schreiber, S.L. and Burakoff, S.J.:
Molecular cloning of a membrane-associated human FK506 and rapamycin binding
protein, FKBP-13. Proc. Natl. Acad. Sci. USA 1991; 88:6677-6681.
22
177. Hahn, W.C., Rosenstein, Y., Burakoff, S.J. and Bierer, B.E.: Interaction of CD2 with its
ligand lymphocyte function associated antigen-3 induces adenosine 3',5'-cyclic
monophosphate production in T lymphocytes. J. Immunol. 1991; 147:14-21.
178. Park, J.K., Rosenstein, Y.J., Bierer, B.E., Remold- O'Donnell, F., Rosen, R.S. and
Burakoff, S.J.: Enhancement of T cell activation by the CD43 molecule whose expression
is defective in Wiskott-Aldrich syndrome. Nature. 1991; 350:706-709.
179. Sleckman, B.P., Rosenstein, Y.J., Igras, V.E., Greenstein, J.L and Burakoff, S.J.:
Glycolipid-anchored form of CD4 increases intercellular adhesion but is unable to enhance
T cell activation. J. Immunol. 1991; 147:428-431.
180. Maziarz, R.T., Groh, V., Prendergast, M, Fabbi, M, Strominger, J.L. and Burakoff, S.J.:
Non-MHC restricted target cell lysis by a CD4-CD8- TCR a/ß T cell line, as well as by
TCR / T cell lines, results from lymphokine-activated killing. Int. J. Cancer 1991;
48:142-147.
181. Rosenstein, Y., Park, J.K., Hahn, W.C., Rosen, F.S., Bierer, B.E. and Burakoff, S.J.:
CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature 1991;
354:233-237.
182. McCarthy, P.L., Abhyankar, S., Neben, S., Newman, G., Sieff, C., Thompson, R.C.,
Burakoff, S.J. and Ferrara, J.L.M.: Inhibition of Interleukin-1 by an Interleukin-1 receptor
antagonist prevents graft-versus-host disease. Blood 1991; 78:1915-1918.
183. Sakamoto, H., Michaelson, J., Jones, W.K., Bhan, A. K., Abhyankar, S., Silverstein, M.,
Golan, D.E., Burakoff, S.J. and Ferrara, J.L.M.: Lymphocytes with a CD4+CD8-CD3phenotype are effectors of experimental cutaneous graft-versus-host disease. Proc. Natl.
Acad. Sci. USA 1991; 88:10890-10894.
184. Antin, J.H., Bierer, B.E., Smith, B.R., Ferrara, J.L.M., Guinan, E.C., Sieff, C., Macklis,
R.M., Tarbell, N.J., Lynch, E., Bouloux, C., Reichert, T., Blythman, H., Rappeport, J.M.,
Burakoff, S.J. and Weinstein, H.J.: Selective depletion of bone marrow T-lymphocytes
with anti-CD5 monoclonal antibodies: effective prophylaxis for graft versus host disease in
patients with hematologic malignancies. Blood 1991; 78:2139-2149.
185. Sen, J., Bossu, P., Burakoff, S.J. and Abbas, A.K.: T cell surface molecules regulating
non-cognate B lymphocyte activation: Role of CD2 and LFA-1. J. Immunol. 1992;
148:1037-1042.
186. Goldman, S.J., Uniyal, S., Ferguson, L.M., Golan, D.E., Burakoff, S.J. and Kiener, P.A.:
Differential activation of phosphotyrosine phosphatase activity in a murine T cell
hybridoma by monoclonal antibodies to CD45. J. Biol. Chem. 1992; 267:6197-6204.
187. Fruman, D.A., Klee, C.B., Bierer, B.E. and Burakoff, S.J.: Calcineurin phosphatase
23
activity in T lymphocytes is inhibited by FK506 and CsA. Proc. Natl. Acad. Sci. USA
1992; 89:3686-3680.
188. Macklis, R.M., Mauch, P.M., Burakoff, S.J. and Smith, B.R.: Lymphoid irradiation results
in long-term increases in natural killer cells in patients treated for Hodgkin's disease.
Cancer 1992; 69:778-783.
189. Collins, T.L., Uniyal, S., Shin, J., Strominger, J.L., Mittler, R.S. and Burakoff, S.J.: p56 lck
association with CD4 is required for the interaction between CD4 and the TcR/CD3
complex and for optimal antigen stimulation. J. Immunol. 1992; 148:2159-2162.
190. Jin. Y-J., Burakoff, S.J. and Bierer, B.E.: Molecular cloning of a 25kDa high affinity
rapamycin binding protein, FKBP25. J. Biol. Chem. 1992; 267:10942-10945.
191. Sleckman, B.P., Shin, J., Igras, V.E., Collins, T.L., Strominger, J.L. and Burakoff, S.J.:
Disruption of the CD4: p56lck complex is required for rapid internalization of CD4. Proc.
Natl. Acad. Sci. USA 1992; 89:7566-7570.
192. Hahn, W., Rosenstein, Y., Calvo, V., Burakoff, S.J. and Bierer, B.E.: A distinctive
cytoplasmic domain of CD2 regulates ligand avidity and antigen responsiveness. Proc.
Natl. Acad. Sci. USA 1992; 89:7179-7183.
193. Hollander, G.A., Luskey, B.D., Williams, D.A. and Burakoff, S.J.: Functional expression
of human CD8 in fully reconstituted mice after retroviral-mediated gene transfer of
hematopoietic stem cells. J. Immunol. 1992; 149:438-444.
194. Kaye, R.E., Fruman, D.A., Bierer, B.E., Albers, M.W., Zydowsky, L.D., Ho. S.I., Jin, Y-J.,
Castells, M.C., Schreiber, S.L., Walsh, C.T., Burakoff, S.J., Austen, F., and Katz, H.R.:
Effects of cyclosporin A and FK506 on FcERI-initiated increases in cytokine mRNA in
mouse bone marrow-derived progenitor mast cells: Resistance to FK506 is associated with
a deficiency in FK506 binding protein 12. Proc. Natl. Acad. Sci. USA 1992; 89:85428546.
195. Moore, J.P., Simpson, G., McKeating, J.A., Burakoff, S.J., Schreiber, S.L. and Weiss,
R.A.: CPF-DD is an inhibitor of infection by human immunodeficiency virus and other
enveloped viruses in vitro. Virology 1992; 188:537-544.
196. Fruman, D., Mather, P., Burakoff, S.J. and Bierer, B.E.: Correlation of calcineurin
phosphatase activity and programmed cell death in murine T cell hybridomas. Eur. J.
Immunol. 1993; 22:2513-2517.
197. Macklis, R.M., Mauch, P.M., Thompson, L., Burakoff, S.J., Smith, B.R.: Phenotypic and
functional analysis of expanded natural killer cell subpopulations in Hodgkin's disease
patients treated with lymphoid irradiation. Oncology 1993; 50:323-328.
198. Hahn, W.C., Burakoff, S.J. and Bierer, B.E.: Signal transduction pathways involved in T
cell receptor-induced regulation of CD2 avidity for CD58. J. Immunol. 1993; 150:260724
2619.
199. Dutz, J.P., Fruman, D.A., Burakoff, S.J. and Bierer, B.E.: A role for calcineurin in
degranulation of murine cytotoxic T lymphocytes. J. Immunol. 1993; 150:2591-2598.
200. Nigam, S., Jin, Y-J., Jin, M-J., Bush, K.T., Bierer, B.E. and Burakoff, S.J: Localization of
the FK506 binding protein, FKBP13, to the lumen of the endoplasmic reticulum.
Biochemical J. 1993; 294:511-515.
201. Jin, Y.J. and Burakoff, S.J.: The 25-kDa FK506-binding protein is localized in the nucleus
and associates with casein kinase II and nucleolin. Proc. Natl. Acad. Sci. USA 1993;
90:7769-7773.
202. Ravichandran, K.S., Lee, K.K., Songyang, Z., Cantley, L.C., Burn, P. and Burakoff, S.J.:
Interaction of Shc with the  chain of the T cell receptor upon T cell activation. Science
1993; 262:902-905.
203. Collins, T.L. and Burakoff, S.J.: Tyrosine kinase activity of CD4 associated p56 lck may
not be required for CD4-dependent T cell activation. Proc. Natl. Acad. Sci. USA 1993;
90:11885-11889.
204. Hendrickson, B.A., Zhang, W., Craig, R.J., Jin, Y-J., Bierer, B.E., Burakoff, S.J. and
DiLella, A.G.: Structural organization of the genes encoding human and murine FK506
binding protein (FKBP13) and comparison to FKBP1. Gene 1993; 134:271-275.
205. Ravichandran, K.S. and Burakoff, S.J.: Evidence for differential intracellular signaling via
CD4 and CD8 molecules. J. Exp. Med. 1994; 179:727-732.
206. Ravichandran, K.S. and Burakoff, S.J.: The adapter protein Shc interacts with the
interleukin-2 (IL-2) receptor upon IL-2 stimulation. J. Biol. Chem. 1994; 269:1599-1602.
207. Hollander, G.A., Widmer, B. and Burakoff, S.J.: Loss of normal thymic repertoire
selection and persistence of autoreactive T cells in graft versus host disease. J. Immunol.
1994; 152:1609-1617.
208. Lorenz, U., Ravichandran, K.S., Pei, D., Walsh, C., Burakoff, S.J. and Neel, B.G.: Lckdependent tyrosyl phosphorylation of the protein tyrosine phosphatase SHPTP-1 in murine
T cells. Mol. Cell. Biol. 1994; 14:1824-1834.
209. Hollander, G.A., Fruman, D.A., Bierer, B.E., and Burakoff, S.J.: Disruption of T cell
development and repertoire selection by calcinuerin inhibition in vivo. Transplant. 1994;
58:1037-1043.
210. Antin, J.H., Weinstein, H.J., Guinan, E.C., McCarthy, P., Bierer, B.E., Gilliland, G.,
Parsons, S., Ballen, K.K., Rimm, I.J., Falarone, G., Bloedow, D.C., Abate, L., Lebsack,
M., Burakoff, S.J., and Ferrara, J.L.M.: Recombinant human interleukin-1 receptor
25
antagonist in the treatment of steroid-resistant graft versus host disease. Blood 1994;
84:1342-1348.
211. Sen, Y., Shinkai, Y., Alt, F.W., Sen, R., and Burakoff, S.J.: Nuclear Factors that mediate
intrathymic signals are developmentally regulated. J. Exp. Med. 1994; 180:2321-2327.
212. Fruman, D.A., Wood, M.A., Gjertson, C.A., Katz, H.R., and Burakoff, S.J., Bierer, B.E.:
FK506 Binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine
mast cells. Eur. J. Immun. 1995; 25:563-571.
213. Sawasdikosol, S., Ravichandran, K., Lee, K., Chang, J.H., and Burakoff, S.J.: Crk interacts
with tyrosine-phosphorylated p116 upon T cell activation. J. Biol. Chem. 1995; 270:28932896.
214. Ravichandran, K., Lorenz, U., Shoelson, S., and Burakoff, S.J.: Interaction of Shc with
Grb2 regulates association of Grb2 with mSOS. Mol. Cell. Biol. 1995; 15: 593-600.
215. Hollander, G.A., Wang, B., Nichogiannopoulou, A., Platenburg, P.P., van Ewijk, W.,
Burakoff, S.J., Gutierrez-Ramos, J.C., and Terhorst, C.: Developmental control point in the
induction of the thymic cortex regulated by a subpopulation of prothymocytes. Nature
1995; 373:350-353.
216. Irie, Y., Ravichandran, K.S., and Burakoff, S.J.: CD8ß chain influences CD8-chain
associated Lck kinase activity. J. Exp. Med. 1995; 181:1267-1273.
217. Venkataraman, L., Burakoff, S.J., and Sen, R.: FK506 inhibits antigen receptor mediated
induction of c-rel in B and T lymphoid cells. J. Exp. Med, 1995; 181:1091-1097.
218. Sen, J., Venkataraman, L., Shinkai, Y., Pierce, J.W., Alt, F.W., Burakoff, S.J., and Sen, R.:
Expression and induction of NF-kB related proteins in thymocytes. J. Immunol.1995;
154:3213-3221.
219. Fruman, D.A., Bierer, B.E., Benes, J.E., Burakoff, S.J., Austen, K.F., and Katz, H.R.: The
complex of FK506-gincing proein 12 and Fk506 inhibits calcineurin phosphatase activity
and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J.
Immunol. 1995; 154:1846-1851.
220. Hollander, G., Simpson, S.J., Mizoguchi, E., Nichogiannopoulou, A., She, J., GutierrezRamos, J-C., Bhan, A.K., Burakoff, S.J., Wang, B., and Terhorst, C.: Severe colitis in
mice with aberrant thymic selection. Immunity, 1995; 2:27-38.
221. Zhou, M-M., Meadows, R.P., Logan, T.M., Yoon, H.S., Wade, W.S., Ravichandran, K.S.,
Burakoff, S.J., and Fesik, S.W.: Solution structure of the Shc SH2 domain complexed
with a tyrosine-phosphorylated peptide from the T-cell receptor. Proc. Natl. Acad. Sci.
USA 1995; 92:7784-7788.
26
222. Fruman, D.A., Pai S-Y., Burakoff, S.J., and Bierer, B.E.: Characterization of a mutant
calcineurin A gene expressed by EL4 lymphoma cells. Mol. Cell Biol. 1995; 15:38573863.
223. Zhou, M-M., Harlan, J.E., Wade, W.S., Crosby, S., Ravichandran, K.S., Burakoff, S.J.,
and Fesik, S.W.: Binding affinities of tyrosine-phosphorylated peptides to the COOHterminal SH2 and NH2-terminal phosphotyrosine binding domain of Shc. J. Biol. Chem.
1995; 52: 31119-31123.
224. Zhou, M-M., Ravichandran, K.S., Olejniczak, E.T., Petros, A.M., Meadows, R.P., Sattler,
M., Harlan, J.E., Wade, W.S., Burakoff, S.J., and Fesik, S.W.: Structure and ligand
recognition of the phosphotyrosine binding domain of Shc. Nature 1995; 378:584-592.
225. Dunussi-Joannopoulos, K., Weinstein, H.J., Nickerson, P.W., Strom, T.B., Burakoff, S.J.,
Croop, J.M., and Arceci, R.J.: Irradiated B7-1 transduced primary acute myelogenous
leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood. 1995;
7:2938-2946.
226. Wesselborg, S., Fruman, D.A., Sagoo, J.K., Bierer, B.E., and Burakoff, S.J.: Identification
of a physical interaction between calcineurin and nuclear factor of activated T cells
(NFATp). J. Biol. Chem. 1995; 271:1274-1277.
227. Ravichandran, K.S., Igras, V., Shoelson, S.E., Fesik, S.W., and Burakoff, S.J.: Evidence
for a role for the phosphotyrosine-binding domain of Shc in Interleukin 2 signaling. Proc.
Natl. Acad. Sci. USA 1995; 93:5275-5280.
228. Hollander, G., Castigli, E., Kulbacki, R., Su, M., Burakoff, S.J., Gutierrez-Ramos, J.C.,
and Geha, R.S.: Induction of alloantigen-specific tolerance to B cells from CD40 null
mice. Proc. Natl. Acad. Sci. 1996; 93:4994-4998.
229. Pratt, J.P., Weiss, M., Sieff, C.A., Shoelson, S.E., Burakoff, S.J., and Ravichandran, K.S.:
Evidence for a physical association between the Shc-PTB domain and the c chain of the
Granulocyte-Macrophage Colony-stimulating factor receptor. J. Biol. Chem. 1996;
271:12137-12140.
230. Sawasdikosol, S., Chang, J.H., Pratt, J.C., Wolf, G., Shoelson, S., and Burakoff, S.J.:
Tyrosine-phosphorylated Cbl binds to Crk after T cell activation. J. Immunol. 1996;
157:110-116.
231. Sen, J., Kapeller, R., Fragoso, R., Sen, R., Zon, L.I., and Burakoff, S.J.: Intrathymic
signals in thymocytes are mediated by p38 mitogen-activated protein kinase. J. Immunol.
1996; 156:4535-4538.
232. Pedraza-Alva, G., Merida, L.B., Burakoff, S.J., and Rosenstein, Y.: CD43 specific
activation of T Cells induces association of CD43 to Fyn kinase. J. Biol. Chem. 1996;
27
271:27564-27568.
233. Lee-Fruman, K.K., Collins, T.L., and Burakoff, S.J.: Role of the Lck Src Homology 2 and
3 domains in protein tyrosine phosphorylation. J. Biol. Chem. 1996; 271: 25003-25010.
234. Lorenz, U., Ravichandran, K., Burakoff, S.J., and Neel, B.G.: Lack of SHPTP1 results in
src - family kinase hyper-activation and thymocyte hyper-responsiveness. Proc. Natl.
Acad. Sci. 1996; 93:9624-9629.
235. Yu, C-L. and Burakoff, S.J. Involvement of proteasomes in regulating Jak-STAT pathways
upon interleukin-2 stimulation. J. Biol. Chem. 1997; 272:14017-14020.
236. Ravichandran, K.S., Zhou, M., Pratt, J.C., Harlan, J.E., Walk, S., Fesik, S.W., and
Burakoff, S.J.: Evidence for a requirement for both phospholipid and phosphotyrosine
binding via the Shc-PTB domain in vivo. Mol. Cell. Biol. 1997; 17:5540-5549.
237. Yu, C-L, Jove, R., and Burakoff, S.J.: Constitutive activation of the Jak-STAT pathway in
T cells overexpressing the Lck protein tyrosine kinase. J. Immunol. 1997; 159:5206-5210.
238. Rameh, L.E., Arvidsson, A-K, Carraway III, K.L., Couvillon, A.D., Rathbun, G.,
Crompton, A., VanRenterghem, B., Czech, M.P., Ravichandran, K.S., Burakoff, S.J.,
Wang, D-S, Chen, C-S, and Cantley, L.C.: A comparative analysis of the phosphoinositide
binding specificity of pleckstrin homology domains. J. Biol. Chem. 1997; 272:2205922066.
239. Hollander, G.A., Zuklys, S., Morel, C., Mizoguchi, E., Mobisson, K., Simpson, S.,
Terhorst, C., Wishart, W., Golan, D.E., Bhan, A.K., and Burakoff, S.J.: Monoallelic
expression of the Interleukin–2 locus. Science 1998; 279:2118-2121.
240. Pedraza-Alva, G., Merida, L.B., Burakoff, S.J., and Rosenstein, Y. T cell activation
through the CD43 molecule leads to Vav tyrosine phosphorylation and mitogen-activated
protein kinase pathway activation. J. Biol .Chem. 1998; 273:14218-14224.
241. Irie, H.Y., Mong. M.S., Itano, A., Crooks, M.E.C., Littman, D.R., Burakoff, SJ. Robey, E.:
The cytoplasmic domain of CD8s regulates lck kinase activation and CD ß T cell
development. J. Immunol. 1998; 161:183-191.
242. Jin, Y-J., Friedman, J., and Burakoff, S.J.: Regulation of tyrosine phosphorylation in
isolated T cell membrane by inhibition of protein tyrosine phosphates. J. Immunol. 1998;
161:1743-1750.
243. Chang, J-H., Pratt, J.C., Sawasdikosol, S., Kapeller, R., and Burakoff, S.J.: The small
GTP-binding protein Rho potentiates AP-1 transcription in T cells. Mol. Cell. Biol. 1998;
18:4986-4993.
244. Gu, H., Pratt, J.C., Burakoff, S.J., and Neel, B.G.: Cloning and characterization of the
28
major SHP-2 binding protein in hematopoietic cells (p97) reveals a novel pathway for
cytokine-induced gene activation. Mol. Cell 1998; 2:729-740.
245. Meng, W., Sawasdikosal, S., Burakoff, S.J., and Eck, M.: Structure of the amino-terminal
domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature 1999; 398:84-90.
246. Van den Brink, M.R.M., Kapeller, R., and Burakoff, S.J.: The extracellular receptor
Kinase (ERK) pathway is required for activation-induced cell death of T cell hybridomas.
J. Biol. Chem. 1999; 274: 11178-11185.
247. Tang, J., Sawasdikosol, S., Chang, J-H, and Burakoff, S.J.: SLAP, a dimeric adapter
protein, plays a functional role in T-cell receptor signaling. Proc. Natl. Acad. Sci. 1999;
96:9775-9780.
248. Pratt, J.C., van den Brink, M.R.M., Igras, V.E., Walk, S.F., Ravichandran, K.S., and
Burakoff, S.J.: Requirement for Shc in T cell antigen receptor-mediated activation of a T
cell hybridoma. J. Immunol. 1999; 163:2586-2591.
249. Jin, Y.J., Yu, C.L. and Burakoff, S.J. Human 70-kDa SHP-1L differs from 68-kDa SHP-1
in its c-terminal structure and catalytic activity. J. Biol. Chem. 1999; 274:28301-28307.
250. McKay, D.B., Irie, H.Y., Hollander, G., Ferrara, J.L.M., Strom, T.B., Li, Y-S. and
Burakoff, S.J.: Antigen-induced unresponsiveness results in altered T cell signaling. J.
Immunol. 1999; 163:6455-6461.
251. Van den Brink, M.R.M., Moore, E., Horndasch, K.J., Crawford, J.M., Hoffman, J.,
Murphy, G.F., and Burakoff, S.J.: Fas-deficient lpr mice are more susceptible to graftversus-host-disease. J. Immunol. 2000; 164:469-480.
252. Yu, C-L., Jin, Y-J. and Burakoff, S.J. Cytosolic tyrosine dephosphorylation of STAT5:
potential role of SHP-2 in STAT5 regulation. J. Biol. Chem. 2000; 275:599-604.
253. Van den Brink, M.R.M., Moore, E., Ferrara, J.L.M. and Burakoff, S.J.: Graft-versus-hostdisease-associated thymic damage results in the appearance of T cell clones with anti-host
reactivity. Transplant. 2000; 69:446-449.
254. Santana MA, Pedraza-Alva G, Olivares-Zavaleta N, Madrid-Marina V, Horejsi V,
Burakoff SJ, Rosenstein Y. CD43-mediated signals induce DNA binding activity of AP1, NF-AT, and NFkappa B transcription factors in human T lymphocytes.
J Biol Chem. 2000; 275:31460-8.
255. Baksh, S., DeCaprio, J.A. and Burakoff, S.J.: Calcineurin regulation of the mammalian
G0/G1 checkpoint element, cyclin dependent kinase 4. Oncogene 2000; 19:2820-2827.
256. Pratt, J.C., Igras, V.E., Maeda, H., Baksh, S., Gelfand, E.W., Burakoff, S.J., Neel, B.G.
and Gu, H.: Gab2 mediates an inhibitory phosphatidylinosital 3' kinase pathway in T cell
29
antigine receptor signaling. J. Immun. 2000; 4158-4163.
257. Van den Brink MRM, Moore E, Horndasch KJ, Crawford JM, Hoffman J, Murphy GF,
Burakoff SJ. Fas ligand-deficient gld mice are more susceptible to graft-versus-host
disease. Transplantation 2000; 70:184-191.
258. Pratt JC, Igras VE, Maeda H, Baksh S, Gelfand EW, Burakoff SJ, Neel BG, Gu H. Cutting
edge: Gab2 mediates an inhibitory phosphatidylinositol 3'-kinase pathway
in T cell antigen receptor signaling. J Immunol. 2000; 165:4158-63.
259. Nishikawa K., Sawasdikosol S., Fruman D. A., Lai J., Songyang Z., Burakoff
S.J.,
Yaffe M.B., Cantley L.C., A peptide library approach identifies a specific inhibitor for the
ZAP-70 protein tyrosine kinase. Mol. Cell 2001; 6:969-974.
260. Schmaltz C., Alpdogan O., Horndasch K.J., Muriglan S.J., Kappel B.J., Teshima
T.,
Ferrara J.L.M., Burakoff S.J., van den Brink M.R.M. Differential use of Fas ligand and
perforin cytotoxic pathways by donor T cell in graft-versus-leukemia effect. Blood 2001;
97: 2886-2895.
261. Friedman J., Rebel V., Derby R., Bell K., Huang T., Kuypers F., Epstein C.,
Burakoff S.J., Absence of mitocondrial superoxide dismutase results in a murine
hemolytic anemia responsive to therapy with a catalytic antioxidant. J. Exp. Med. 2001;
193:925-934.
262. Su M., Yu C-L., Burakoff S.J., Jin YJ, Targeting Src homology 2 domain-containing
tyrosine phosphatase (SHP-1) into lipid rafts inhibits CD-3-induced T Cell activation, J.
Immun. 2001; 166:3975-3982.
263. Slavik J.M., Lim D., Burakoff S.J., Hafler D.A., Uncoupling p70 s6 kinase
activation
and proliferation: rapamycin-resistant profileration of human CD8+ T lymphocytes. J.
Immun., 2001; 166:3201-3209.
264. Pedraza-Alva G, Sawasdikosol S, Liu YC, Merida LB, Cruz-Munoz ME,
Oceguera-Yanez F, Burakoff SJ, Rosenstein Y. Regulation of Cbl molecular
interactions by the co-receptor molecule CD43 in human T cells. J Biol Chem. 2001; 72937.
265. Friedman JS, Rebel VI, Derby R, BellK. Huang TT, Kuypers FA, Epstein CJ,
Burakoff SJ, Absence of mitochondrial superoxie dismutase results in a murine
hemolytic anemia responsive to therapy with a catalytic antioxidant. J Exp Med. 2001:
193; 925-34.
266. TkaczukJ, Yu CL, Baksh S, Milford EL, Carpenter CB, Burakoff SJ, McKay DB.
Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.
Am J Transplant; 2002: 2:31-40.
267. Ordemann R, Hutchinson R, Friedman J. Burakoff SJ, Reddy P, Dufner U, Braun
M, Liu C, Teshima T, Ferrara JL; Enhanced allostimulatory activity of host
antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin
30
Invest. 2002:109: 1249-56.
268. Mulroy T, McMahon JA, Burakoff SJ, McMahon AP, Sen J. Wnt-1 and Wn-4
regulate thymic cellularity. Eur J Immunol. 2002; 32:967-71.
269.Baksh S, Widlund H, Frazer-Abel AA, Du J, Fosmire S, Fisher DE, DeCaprio JA.
Modiano JF, Burakoff SJ. NFATc2-mediated repression of cyclin-dependent
kinase 4 expression. Mol. Cell. 2003; 10: 1071-81.
270. Fragoso R, Ren D, Zhang X, Su M, Burakoff SJ, Jin Y. Lipid Raft distribution of
CD4 Depends on its Palmitoylation and Association with Lck: Evidence for CD4
induced lipid raft aggregation as an additional mechanism to enhance CD3
signaling. J. Immun. 2003 Jan 15; 170(2): 913-921.
271.Sawasdikosol S, Russo KM, Burakoff SJ. Hematopietic progenitor kinase 1 (HPKl)
negatively regulates prostaglandin E2-induced fos gene transcription. Blood. 2003;
101: 3687-3689.
272. Slavik JM, Lim DG, Burakoff SJ, Hafler DA, Rapamycin-resistant proliferation of
CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is
prevented by an inhibitor of phosphoinositie 3-kinase activity. J Biol Chem. 2004;
Jan 9; 279(2):910-9.
273. Friedman JS, Lopez, MF, Fleming MD, Rivera A, Martin FM, Welsh ML, Boyd AS,
Doctrow SR, Burakoff SJ. SOD2 Deficiently anemia: protein oxidation and
altered protein expression reveal targets of damage, stress response and antioxidant responsiveness. Blood. 2004; 104:2565-2573.
274. Friedman, JS, .Alpdogan O, van den Brink, MR, Liu C, Hurwiz D, Boyd A,
Kupper TS, Burakoff SJ. Increasing T cell age reduces effector activity but
preserves proliferative capacity in a murine allogeneic major histocompatibility
complex-mismatched bone marrow transplant model. Biol Blood Marrow
Transplant. 2004; 10: 448-460.
275. Frazer-Abel AA, Baksh S, Fosmire SP, Willis D, Pierce AM, Meylemans H,
Linthicum DS, Burakoff, SJ, Coons T, Bellgrau D. Nicotine activates
NFATc2 and prevents cell cycle entry in T cells, J Pharmacol Exp Ther. 2004;
311: 758-769.
276. Su MW, Pyarajan S, Chang JH, Yu CL.Jin, YJ, Stierhof YD, Walden P, Burakoff SJ.
Fratricide of CD8+ cytotoxic T Lymphocytes is dependent on cellular activation and
perforin-mediated killing. Eur J Immunol. 2004; 34: 2459-2470.
277. Zambricki E, Shigeoka A, Kishimoto, H, Sprent J, Burakoff S, Carpenter C,
Milford E, McKay D. Signaling T cell survival and death by IL-2 and IL-15. Am J
Transplant. 2005; 11:2623-2631.
31
278. Jin JJ, Yi Cai C, ,Zhang X, Zhang HT, Hirst JA, Burakoff SJ. HIV Nef-mediated
CD4 down-regulation is adaptor protein complex 2 dependent. J. Immun 2006;
Feb 15;176(4):2669.
279. Fragoso R, Pyarajan S, Irie HY, Burakoff SJ. CD8/Lck transgene is able to drive
thymocyte differentiation. J. Immun. 2006; 6008-6015.
280.
Mathews JP, Taylor BS, Bader GD, Pyarajan S, Antoniotti M, Chinnaiyan AM, Sander
C, Burakoff SJ, Mishra B. From bytes to bedside: data integration and computational
biology for translational cancer research. PLoS Comput Biol. 2007 Feb 23; 3 (2): e12.
281.
Sawasdikosol S, Pyarajan S, Alzabin, S, Matejovic G, Burakoff, SJ. Prostaglandin E2
activates HPK1 activity via a PKA-dependent pathway. J Biol Chem. Nov 2007, 282:
34693-34699.
282.
Pyarajan, S, Matejovic G, Pratt JC, Baksh S, Burakoff SJ. IL-3 Induced C-FOS
activation is modulated by GAB2-Calcineurin Interaction. J. Biol. Chem., Jun 2008;
283:23505-9.
283.
Jin, Y.J., C. Y. Cai, X. Zhang, H. T. Zhang, and S. J. Burakoff. Lysine144, a Ubiquitin
Attachment Site in HIV-1 Nef, Is Required for Nef-mediated CD4 Down regulation. J
Immunol. 2008; 108:787-86.
284.
Alzabin S, Bhardwaj N, Kiefer F, Sawasdikosol S, Burakoff S. Hematopoietic
progenitor kinase 1 is a negative regulator of dendritic cell activation. J Immunolo.
2009; 182: 6187-94.
285.
Alzabin S, Pyarajan S,Yee S,Friedemann K, Suzuki A, Burakoff S, Sawasdikosol.
Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated
suppression of the anti-tumor immune response. Cancer Immunology, Immunotherapy,
in press 2009.
Reviews and book chapters:
1.
Benacerraf, B., and Burakoff, S.J.: The biological significance of alloreactivity. In: The
Proceedings of the Workshop on Genetic Control of Autoimmune Disease. N. Rose.
Elsevier North-Holland Press 1978; 321-326.
2.
Burakoff, S.J.: Specificity of cytolytic T-cell responses. In: The Role of the Major
Histocompatibility Complex in Immunobiology. Ed., M.E. Dorf. Garland Press, New
York 1980; 343-371.
3.
Burakoff, S.J., Reiss, C.S., Finberg, R., and Mescher, M.F.: Cell-mediated immunity to
viral glycoproteins. Reviews of Infectious Diseases 1980; 2:62-77.
32
4.
5.
Burakoff, S.J., and Mescher, M.F.: Reconstituted membranes and liposomes in the study
of lymphocyte interactions. In: Cell Surface Reviews. Eds., G. Poste and G.L. Nicolson.
Elsevier Biomedical Press, Amsterdam 1982; 173-214 .
Mescher, M.F., Balk, S.P., Burakoff, S.J., and Herrmann, S.H.: Cytolytic T lymphocyte
recognition of subcellular antigen. In: Mechanisms of Cell Mediated Cytotoxicity. Eds.,
W.R. Clark and P. Goldstein. Plenum Press, New York 1982; 41-55.
6.
Reiss, C.S., and Burakoff, S.J.: Genetic regulation of the cytolytic T lymphocyte
response to influenza viruses. In: Ir Genes: Past, Present, and Future. Eds., C.W. Pierce
et al. Humana Press, New Jersey 1983; 401-405.
7.
Germain, R.N., Weinberger, O., Rock, K., and Burakoff, S.J.: Involvement of syngeneic
Ia in T cell responses to class I alloantigens. In: Ir Genes: Past, Present, and Future. Eds.
C.W. Pierce et al. Humana Press, New Jersey 1983; 367-375.
8.
Krensky, A.M., and Burakoff, S.J.: Cytotoxic T-lymphocyte response to HLA antigens.
J. Pediatrics 1983; 102:814-819
9.
Burakoff, S.J., Clayberger, C., Hemler, M., Krensky, A.M., Reiss, C.S., Robbins, E.,
Sanchez-Madrid, F., Springer, T.A., Strominger, J.L., and Ware, C.F.: Cytotoxic T cells
directed against HLA-DR antigens and their surface proteins. Diagnostic Immunol.
1983; 1:116-119.
10.
Duprez, V., and Burakoff, S.J.: Cytolytic T lymphocyte response to Moloney Sarcoma
Virus. Survey Immunol. Res. 1983; 2:309-311.
11.
Burakoff, S.J., Lipton, J.M., and Nathan, D.G.: Recapitulation of the immune response
and hematopoietic system in bone marrow transplantation. Clinics in Hematology 1983;
12:695-720.
12.
Burakoff, S.J.: Cell-mediated cytotoxicity: An overview. Federation Proceed. 1984;
43:266-267.
13.
Reiss, C.S., Evans, G.A., Murre, C., Margulies, D.H., Seidman,J.G., and Burakoff, S.J.:
Cytotoxic T lymphocyte recognition of class I H-2 antigens following DNA-mediated
gene transfer. Federation Proceed. 1984; 43:271-275.
14.
Krensky, A.M., Sanchez-Madrid, F., Springer, T.A., and Burakoff, S.J.: Human
lymphocyte function associated antigens. Survey Immunol. Res. 1984; 3:39-44.
15.
Gorga, J.C., Foran, J., Burakoff, S.J., and Strominger, J.L.: Use of the HLA-DR antigens
incorporated into liposomes generate HLA-DR specific cytotoxic T lymphocytes.
Methods in Enzymology 1984; 108:607-613.
16.
Greenberger, J.S., Sakakeeny, M.A., Krensky, A., Burakoff, S., Reid, D., Novak, T.,
Boggs, S.S., and Davison, M.: Experimental evidence for the potential usefulness of
33
permanent IL-3 dependent multipotential hematopoietic progenitor cell lines in
transfusion granulocyte support therapy: Need for expansion of early passage cells.
Proc. Symp. on Long Term Bone Marrow Cultures. A.R. Liss, New York 1984; 18:255269.
17.
Burakoff, S.J., Weinberger, O., Krensky, A.M., and Reiss, C.S.: A molecular analysis of
the cytolytic T lymphocyte response. Adv. Immunol. 1984; 36:45-85.
18.
Pober, J.S., Gimbrone, M.A., Jr., Collins, T., Cotran, R.S., Ault, K.A., Fiers, W.,
Krensky, A.M., Clayberger, C., Reiss, C.S., and Burakoff, S.J.: Interactions of T
lymphocytes with human vascular endothelial cells: Role of endothelial cell surface
antigens. Immunobiol. 1984; 168:483-494.
19.
Krensky, A.M., Clayberger, C., Greenstein, J.L., Collins, T., Pober, J.S., Robbins, E.,
Anderson, D., Springer, T.A., and Burakoff, S.J.: Cell surface structures involved in the
human cytolytic T lymphocyte response. In: Regulation of the Immune System, Vol. l8.
Eds., E. Sercarz, H. Cantor, and L. Chess. Alan R. Liss, New York l984; 209-219.
20.
Flyer, D.C., Burakoff, S.J., and Faller, D.V.: Expression and CTL recognition of cloned
subgenomic fragments of Moloney murine leukemia virus in murine cells. Survey
Immunol. Res. 1985; 4(2):168-172.
21.
Mentzer, S.J., Barbosa, J.A., Krensky, A., Biro, P.A., Strominger, J.L., and Burakoff,
S.J.: Species-specific cytotoxic T lymphocyte recognition of major histocompatibility
antigens HLA-A2 and HLA-B7 after DNA-mediated gene transfer. Transplant. Proceed.
1985; 17:969-971.
22.
Burakoff, S.J.: Helper cells are necessary for cytotoxic T cell activation. Transplant.
Proceed. 1985; 17:1546-1548.
23.
Krensky, A.M., Mentzer, S.J., Greenstein, J.L., Crimmins, M., Clayberger, C., Springer,
T.A., and Burakoff, S.J.: Human cytolytic T-lymphocyte clones and their functionassociated cell surface molecules. In: Hybridoma Technology in the Biosciences and
Medicine. Ed., T. Springer. Plenum Press, New York 1985; 559-573.
24.
Springer, T.A., Rothlein, R., Anderson, D.C., Burakoff, S.J., and Krensky, A.M.: The
function of LFA-l in cell-mediated killing and adhesion: Studies on heritable LFA-l,
Mac-l deficiency and pl50,95 on lymphoid cell self-aggregation. In: Mechanisms of
cell-mediated cytotoxicity II. Eds. P. Henkart and E. Martz. Plenum Press, New York
1985;311-322.
25.
Mentzer, S., Greenstein, J., Krensky, A.M., and Burakoff, S.J.: Functional cell surface
antigens involved in human cell mediated cytotoxicity. In: Human T Cell Clones. Eds.,
M. Feldmann, J.R. Lamb, and J.N. Woody. Humana Press, New Jersey, 1985;187-196.
34
26.
27.
Ferrara, J., Mauch, P., Murphy, G., and Burakoff, S.J.: Bone marrow transplantation:
The genetic and cellular basis of resistance to engraftment and acute graft versus host
disease. Survey Immunol. Res. 1985;4:253-263.
Reiss, C.S., Burakoff, S.J., Seidman, J.G., and Murre, C.: T cell recognition elements on
class I MHC gene products which restrict antiviral CTLs. In: Options for the Control of
Influenza, Vol. 36. Alan R. Liss, New York, 1986: 435-444.
28.
Mentzer, S.J., Bierer, B., Crimmins, M., Greenstein, J.L., and Burakoff, S.J.: Functional
T cell antigens and their role in T cell activation. In: Eibl, M.M., Rosen, F.S., eds.
Primary Immunodeficiency Diseases. Amsterdam: Elsevier Science Publishers,
1986;165-171.
29.
Burakoff, S.J., Greenstein, J.L., Weinberger, O., and Herrmann, S.H.: Reconstituted
membranes and liposomes in the induction of the cytolytic T lymphocyte response. In:
Vaccines 1986. Eds., R. Channock, R. Lerner, and F. Brown. Cold Spring Harbor Press,
New York, 1986; 119-122.
30.
Greenstein, J.L., Mentzer, S.J., and Burakoff, S.J.: The role of accessory molecules in T
cell recognition. In: Handbook of Cytolytic Lymphocyte Clones and Complement as
Effectors of the Immune System. Ed., E.A. Podack. CRC-Press, Inc.; 1988,127-142.
31.
Bierer, B.E., Mentzer, S.J., Greenstein, J.L., and Burakoff, S.J.: The role of functional
cell surface antigens in T cell activation. In: Cruse JM, Lewis RE, eds. The Year in
Immunology, 1985-86. Basel:Karger, 1986; 2:39-59.
32.
Flyer, D.C., Faller, D.V., and Burakoff, S.J.: Antigenic requirements for the recognition
of Moloney murine leukemia virus-induced tumors by cytotoxic T lymphocytes. In:
Induction and Recognition of the Transformed Cell. Eds., M. Greene and T. Hamaoka.
Plenum Press, New York, 1987;221-230.
33.
Mentzer, S.J., Bierer, B.E., Crimmins, M.A.V., Greenstein, J.L., and Burakoff, S.J.:
Functional cell surface molecules in the CTL-target cell interaction. In: Membrane
Mediated Cytotoxicity. Eds., B. Bonavida and J. Collier. Alan R. Liss, New York,
1987;473-484.
34.
Anderson, M.J., Rappeport, J., Ault, K.A., Burakoff, S.J., and Smith, B.R.: Clinical
correlates of unusual circulating lymphocytes appearing post marrow transplantation
(BMT). In: Recent Advances in Bone Marrow Transplantation. Eds., R.P. Gale and R.
Champlin. Alan R. Liss, New York, 1987;659-678.
35.
Burakoff, S.J.:
Cell-mediated cytotoxicity:
1984;43(2):266-267.
36.
Greenstein, J.L., Sitkovsky, M.V., and Burakoff, S.J.: Distinct roles for L3T4 in T cell
activation. Fed. Proceed. 1987;46(2):313-316.
35
An overview. Fed. Proceed.
37.
Burakoff, S.J. and Bierer, B.E.: Cellular immunology. In: Yearbook of Science and
Technology-1988. McGraw Hill, New York, 1987;48-50.
38.
Greenstein, J.L., and Burakoff, S.J.: The role of L3T4 (CD4) in T cell activation.
Annales de l'Institut Pasteur 1987;138:134-138.
39.
Ferrara, J., Marion, A., Murphy, G. and Burakoff, S.J.: Acute graft-versus-host
disease:pathogenesis and prevention with a monoclonal antibody in vivo. Transplant.
Proceed. 1987;19:2662-2666.
40.
Bierer, B.E., Greenstein, J.L., Sleckman, B., Ratnofsky, S., Peterson, A.,
Seed, B.,
and Burakoff, S.J.: Functional analysis of the cell surface antigens CD2, CD4, and CD8
in T-cell activation In Cytotoxic T cells. N. Y. Acad. Sci.,1988;199-206.
41.
Mentzer, S.J., Wilson,R., Burakoff, S.J. and Herrmann, S.H.: Membrane bound antiCD3 monoclonal antibody trigger cytolytic T lymphocyte-mediated tumor lysis. Archive
Surg. 1988;123910):1280-1285.
42.
Bierer, B.E., Peterson, A., Park, J., Remold-O'Donnell, E., Rosen, F.S., Seed, B., and
Burakoff, S.J.: T cell activation: The T cell erythrocyte receptor (CD2) and sialophorin
(CD43). In Allergy and Immunology Clinics of North America. 1988;51-68.
43.
Santos-Aguado, J., Crimmins, M.A.V., Mentzer, S.J., Strominger, J.L., and Burakoff,
S.J.: Molecular characterization of allospecific cytotoxic T lymphocytes recognition
sites in the HLA-A2 molecule using oligonucleotide-generated site-specific mutants.
Ed., B. Dupont, Springer-Verlag, New York. Immunobiology of HLA, 1989;297:97100.
44.
Bierer, B.E., and Burakoff, S.J.: T cell adhesion molecules. The FASEB J. 1988;2:25842590.
45.
Sleckman, B.P., Ratnofsky, S.E., Bierer, B.E., Burakoff, S.J.: The T cell receptors. ISI
Atlas of Science: Immunology. 1988;1:74-78.
46.
Bierer, B.E., Jones, W.J., Sen, J., Burakoff, S.J.: Human CD2, a T cell receptor involved
in T cell activation, and the murine CD2 homologue. In Cellular Basis of Immune
Modulation. Eds., J.G. Kaplan. D.R. Green, R.C. Bleackley, Alan R. Liss, New
York.1988;123-133.
47.
Ferrara, J.L.M., Wall, D.A., van Dijken, P.J., Macklis, R.M., Abbas, A.K., and Burakoff,
S.J.: Graft versus host disease: Mechanisms of immunodeficiency and monoclonal
antibody therapy. In Recent Advances in Bone Marrow Transplantation. Eds. R.P. Gale
and R. Champlin. Alan R. Liss, New York., 1988;91:411-422.
48.
Bierer, B.E., Sleckman, B., Ratnofsky, S. and Burakoff, S.J.: The biological roles of
CD2, CD4 and CD8. Ann. Rev. Immunol. 1989;7:579-599.
36
49.
Goldman, S.J., Bierer, B.E., and Burakoff, S.J.: Analysis of CD4 and CD2 receptor
function in Immune System and Cancer. Eds. Hamaoka, T., Hodes, R.J., Klein, G.,
Sugimura, T., Takayama, S., Yamamura, Y. Japan Sci. Soc. Press., Tokyo, 1989;149160.
50.
Bierer, B., Bogart, R.E., Wolff, H.L., and Burakoff, S.J.: Functional analysis of antiCD2 MAbs reactivity. Ed. Knapp W. In: Leukocyte typing IV. White Cell
Differentiation Antigens. Oxford University Press, Oxford, 1989;274-277.
51.
Bierer, B.E. and Burakoff, S.J.: T lymphocyte activation: The biology and function of
CD2 and CD4. Immunol. Rev. 1989;111:267-294.
52.
Strominger, J.L., Santos-Aguado, J., Burakoff, S.J., Vega, M.A., Gotch, F.M., Robbins,
P.A., and McMichael, A.M.: Mutants of HLA-A2 in the analysis of its structure and
function. Antigen Recognition, Cold Spring Harbor Symposium Press, New York,
1989;361-363.
53.
Burakoff, S.J. and Eichmann, K.: Discussion Summary: Cell adhesion molecules and
their expression. In: Immunogenicity. Eds. C. Janeway, E. Sercarz and J. Sprent. Alan R.
Liss, New York, 1990;103-108.
54.
Goldman, S.J., Mittler, R.S., Veillette, A. and Burakoff, S.J.: The role of CD4 in T cell
activation. In: Immunogenicity. Eds. C. Janeway, E. Secarz and J. Sprent. Alan R. Liss,
New York, 1990;93-102.
55.
Jones, W.K., Sen, J. and Burakoff, S.J.: Murine CD2: Structure, expression and
recognition of human LFA-3. In Yearbook of Immunol. Eds., J. Cruse, and R.E. Lewis,
Jr., Karger, Basel. 1989-1990;6:95-111.
56.
Ferrara, J. and Burakoff, S.J.: Acute GVHD: Pathophysiology in a murine model. In
Graft versus host disease: Immunology, Pathophysiology and Treatment. Eds. Burakoff,
S.J., Deeg, J., Ferrara, J., and Atkinson, K. Marcel Dekker, New York., 1990;9-29.
57.
Bierer, B.E., and Burakoff, S.J.: T cell receptors: adhesion and signaling. Adv. Cancer
Research. Eds., G. VanderWoude and G. Klein. 1991;56:49-76.
58.
Antin, J.H., Bierer, B.E., Smith, B.R., Guinan, E.C., Provost, M., Ferrara, J., Macklis,
R., Tarbell, N.J., Blythman, H., Bouloux, C., Zinniti, L., Bogart, R., Burakoff, S.J.,
Weinstein, H.: Selective depletion of bone marrow T-lymphocytes with an anti-CD5
monoclonal immunotoxin (ST-1 Immunotoxin): Effective prophylaxis for graft versus
host disease. In: Bone Marrow Purging and Processing. Alan R. Liss, New York,
1990;207-215.
37
59.
Diamond, D.C., Bowman, M.R., MacFerrin, K., Schreiber, S.L., and Burakoff, S.J.:
CD4: Function, structure and its interactions with the HIV-1 envelope protein, gp120.
In: Viruses that affect the immune system. Eds., H. Fan, I. Chen, N. Rosenberg and W.
Sugden. Am. Soc. Micro. 1990;93-102.
60.
Mentzer, S.J., Burakoff, S.J., and Barbosa, J.A.: Induction of HLA class I surface
expression recruits low-affinity cytolytic T lymphocytes. Int. Arch. Allergy Appl.
Immunol. 1990;91(4);437-440.
61.
Silberman, S.L., Goldman, S.J., Mitchell, D., Tong, A., Rosenstein, Y., Diamond, D.,
Finberg, R., Schreiber, S., and Burakoff, S.J.: The interaction of CD4 with HIV-1
gp120. Semin. Immunol. 1991;3(3):187-192.
62.
Bierer, B.E., Jin, Y-J, Fruman, D.A., Calvo, V. and Burakoff, S.J.: FK506 and
rapamycin: molecular probes of T-lymphocyte activation. Transplant. Proceed.
1991;23:2850-2855.
63.
Rosenstein, Y., Park, J., Bierer, B.E. and Burakoff, S.J.: The Wiskott-Aldrich
Syndrome: An immunodeficiency associated with defects of the CD43 molecule. In:
Gupta, S. and Griscelli, G.New Concepts in Immunodeficiency Diseases. Chichester,
England:John Wiley & Sons, 1993;249-268.
64.
Burakoff, S.J., Collins, T., Hahn, W.C., Park, J.K., Sleckman, B.P., Igras, V.,
Rosenstein, Y. and Bierer, B.E.: The role of co-receptors in T cell activation. In Gergely
J, Benczur M, Erdei A, Falus A, Fust G, Medgyesi G, Petranyi G, Rajnauolgyi E, eds.
Progress in Immunology VIII. Berlin: Springer-Verlag, 1993;8:275-281.
65.
Fruman, D.A., Burakoff, S.J. and Bierer, B.E.: Molecular actions of cyclosporin A,
FK506 and rapamycin. In: Thomson, AW and Starzl, T., Immunosuppressive Drugs:
Developments in Anti-Rejection Therapy. Edward Arnold Kent, United Kingdom,
1994;15-36.
66.
Collins, T.L., Hahn, W.C., Bierer, B.E. and Burakoff, S.J.: CD4, CD8 and CD2 in T cell
adhesion and signaling. In: Dunon, D., Mackay, C.R., Imhof, B.A. eds. Adhesion in
Leukocyte Homing and Differentiation. Berlin:Springer-Verlag, 1993;184:223-233.
67.
Burakoff, S.J. and Lafferty, K.J.: Editorial overview. Antigen, Co-stimulators and
cytokines: regulators of allogeneic interactions. Current Opin. Immunol. 1993;5:745773.
68.
Bierer, B.E., Hollander, G., Fruman, D. and Burakoff, S.J.: Cyclosporin A and FK506:
Molecular mechanisms of immunosuppression and probes for transplantation biology.
Current Opin. Immunol. 1993;5:763-773.
69.
Ravichandran, K.S. and Burakoff, S.J.: Differential signaling by CD4 and CD8
38
molecules and the role of Shc in T cell receptor-mediated Ras activation.
Transplantation Immunobiology, Eds., Orosz, C. and Steinmuller, D. Transplant. Sci.
1993;3:143-146.
70.
Collins, T.L. and Burakoff, S.J.: CD4 and Lck in T cell activation. In: Current Topics in
Mucosal Immunology. Eds., M. Tsuchiya, J. Yodoi, T. Hibi and S. Miura Excepta
Medica, Tokyo, 1994;39-47.
71.
Fruman, D.A., Burakoff, S.J. and Bierer, B.E.: Immunophilins in protein folding and
immunosuppression. FASEB J. 1994;8:391-400.
72.
Hollander, G.A., Bierer, B.E. and Burakoff, S.J.: Molecular and biological actions of
CsA and FK506 on T cell development and function. In: Deeg J, Ed. Transfusion
Science, 1994;15:207-228.
73.
Collins, T.L., Kassner, P.D., Bierer, B.E. and Burakoff, S.J.: Adhesion receptors in
lymphocyte activation. Current Opin. Immunol., Philadelphia, PA: Current Science,
1994;6:385-393.
74.
Ravichandran, K.S., Collins, T.L. and Burakoff, S.J.: CD4 and signal transduction. In:
The CD4 Molecule. Roles in T lymphocytes and in HIV Disease. Ed. Littman, D.
Springer-Verlag, 1996:47-62.
75.
Ravichandran, K.S., Pratt, J.C., Sawasdikosol, S., Irie, H.Y., Burakoff, S.J.: Coreceptors
and adapter proteins in T cell signaling. Ann. N.Y. Acad. Sci. 1995;766:117-133.
76.
Vander Woude, A.C., Fruman, D.A., Burakoff, S.J., and Bierer, B.E.: Progress in
therapeutic immunosuppression: cyclosporine, Tacrolimus (FK506), and Rapamycin. In
Therapeutic Immunology. Eds., Austin, F., Burakoff, S.J., Rosen, F., Strom, T.B.1996;
Blackwell Science:71-87.
77.
Hollander, G.A., Bierer, B.E., and Burakoff, S.J.: Molecular mechanisms of
immunosuppressive drugs; cyclosporine A, FK506 and Rapamycin. In Transplantation
Biology: Cellular and Molecular Aspects. Eds., Tilney, N.L., Strom, T.B. and Paul, L.C.
1996:657-673.
78.
Fruman, D.A., Pai, S.-Y., Klee, C.B., Burakoff, S.J. and Bierer, B.E.: Measurement of
calcineurin phosphatase activity in cell extracts. ImmunoMethods, 1996;9:146-154.
79.
Pratt, J.C., Ravichandran, K.S., Sawasdikosol, S., Chang, J.H., Burakoff, S.J.
Multifunctional roles of adapter proteins in T-cell signaling. The Immunologist.
1996;122-127.
80.
Lee-Fruman, K.K., Irie, H.Y., Burakoff, S.J. T cell co-receptors in tumor immunity:
39
CD4 and CD8 cells, structure and function. Encyclopedia of Cancer. Academic Press,
1997;3:1724-1735.
81.
Hollander, G.A., Burakoff, S.J. Thymic T-cell development. Graft-vs.-host disease.
Eds. Ferrara, J., Burakoff, S.J., Deeg, H.J., Marcel Dekker, Inc.1997:1-40.
82.
Pratt, J.C., Sawasdikosal, S., van den Brink, M.R.M., Burakoff, S.J. Postitive and
negative signaling pathways. Transplant. Proceed. 1999;31:772-774.
83.
Sen, J., Burakoff, S.J. Signal transduction of thymic development. Developmental
Biology of Hematopoiesis. Ed. Zon, L. Oxford University Press, Oxford England. 1999
84.
McKay, D.B., and Burakoff, S.J., Biochemical basis of allograft tolerance. Graft, 2000;
Vol. 3.
85.
Baksh S., and Burakoff, S.J. The role of calcineurin in T lymphocyte activation.
Seminars in Immunol. 2000; 12: 405-415.
86.
Baksh S, Freidman J.S., Burakoff, S.J., Bierer, B.E. Immunosuppressants and
immunophilin binding agents: Current research and clinical applications. In: Austen,
F., Burakoff, S.J., Rosen, and Strom, T.: Therapeutic Immunology. New York:
Academic Press Inc. 2000: 81-103.
87.
Sawasdikosol S., Pratt, J.C., Meng, W., Eck, M.J., Burakoff, S.J. Adapting to multiple
personalities: Cbl is also a RING finger ubiquitin ligase. Biochimica et Biophysica
Acta. 2000: 1471-1-12.
88.
van den Brink, M.R.M., Burakoff S.J., Cytolytic pathways in stem cell transplantation.
Nature Rev. Immunol. 2002; 4: 273-281.
89.
Fragoso, R.C, Su, M. W-c, Burakoff, S.J. T Cells and their effector functions. In:
Bertino, JR: Encyclopedia of Cancer. New York: Academic Press Inc. 2002; Vol I: 339352.
90.
Mathew, J.P., Taylor, B.S., Bader, G.D., Pyarajan, S., Antoniotti, M., Chinnaiyan, A.M.,
Sander, C., Burakoff, S.J., Mishra, B. From Bytes to Bedside: Data Integration and
Computational Biology for Translational Cancer Research. PLoS Computational
Biology. February 2007, Volume 3, Issue 2.
Books
1.
Burakoff, S.J., Ferrara, J., Deeg, H.J., Atkinson, K.: Graft-versus-Host Disease:
Immunology, Pathophysiology, and Treatment. Marcel Dekker, Inc. New York and
Basel, 1990.
2.
Austin, F.K., Burakoff, S.J., Rosen, F., Strom, T.: Therapeutic Immunology. Blackwell
Science, 1996.
40
3.
4.
Ferrara, J., Burakoff, S.J., Deeg, H.J. Graft versus Host Disease. Immunology,
Pathophysical and Treatment. 2nd Edition. Marcel Dekker, Inc. New York and Basel,
1997.
Austin, F.K., Burakoff, S.J., Rosen, F., Strom, T.: Therapeutic Immunology 2nd
Edition. Blackwell Science, 2001.
41